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ENGLISH SUMMARY 
Background  
This Ph.D. review addresses 3 problems with relevance to myocardial infarction 
(MI). (1) The mortality rate due to ischemic heart disease has declined in western 
countries. Changes in MI risk factors and treatment strategies may have potentially 
influenced incidence and mortality rates. However, the change in risk factors was 
not similar in all age and gender groups. Therefore, the changes over time in 
incidence and mortality rates associated with MI in various age and gender groups 
are important factors to understand. (2) There are established medical treatments 
and revascularization recommendations for MI patients with stenosis of coronary 
vasculature. Nevertheless, many MI patients have no significant stenosis, and these 
patients do not receive the same medical treatment as those with significant 
stenosis. Therefore, the prognosis of those without stenosis need further study.     
(3) Costs of admissions for patients with MI and suspected MI comprise a huge 
burden on the health care system. One aspect of that lies in the management of 
patients admitted with suspected acute coronary syndrome. Before patients can be 
discharged from the hospital, a routine draw of three or more blood samples of 
cardiac troponin must be taken before ruling out MI. This routine practice leads to 
extended hospital stays and increased costs. The cost-effectiveness of this approach 
has not been examined until now.  
Objectives: The following aims in this thesis address these unresolved aspects of 
MI incidence, prognosis, and health care costs:  
1. To examine temporal trends in myocardial infarction incidence and mortality 
according to age and gender in Denmark over a 35-year period (1978-2012). 
2. To investigate long-term outcomes of patients with non-ST-segment elevation 
myocardial infarction according to coronary artery pathology on the angiography.  
3. To analyse the cost-effectiveness of the third blood sample to measure troponin 
in patients admitted with a suspected non-ST-segment elevation acute coronary 
syndrome. 
 
Methods  
 
Studies I and II were historical prospective studies in which data collected from 
different Danish registries were used. Study I included patients aged ≥30 years 
admitted for first time MI to all Danish hospitals between 1978-2012 (n=316.790). 
Mortality status was collected from Danish Civil registry. 
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Study II included 8.889 patients admitted for first time non-ST-segment elevation 
myocardial infarction (NSTEMI) to hospitals in western Denmark, who underwent 
coronary angiography within 30 days during 2000-2011. Patients were classified as: 
zero-vessel disease (0-vessel group) indicating angiographically normal coronary 
arteries or very mild atherosclerosis; diffuse atherosclerosis (atherosclerosis group) 
indicating moderate focal or diffuse atherosclerosis without stenosis ≥50%, one-
vessel disease (1-vessel group), two-vessel disease (2-vessel group), and three-
vessel disease (3-vessel group) with stenosis ≥50%. Follow-up period: 13 years 
(median 4.5) to 31/12/2012.  
 
Study III was a cost-effectiveness analysis of the third blood sample of cardiac 
troponin. This study included 534 consecutive patients admitted for suspected non-
ST-segment elevation acute coronary syndrome at Aalborg University Hospital 
between March and November 2003. Three blood samples, 6-12 hours apart, to 
analyse troponin were drawn from all patients according to the department's 
practice guidelines.  
The cost of troponin analysis (Euro 12) and one day stay in Coronary Care Unit 
which estimated to be Euro 1,550 were obtained. The extended length of stay due to 
the third blood sample was estimated to be 0.5 days on average. The effectively was 
measured by the impact of the third troponin blood sample on clinical decision 
making and management plan. 
 
Results  
 
In Study I: first MI incidence per 100.000 person-years (/10
5 
p-y.) decreased 
significantly among males from 500 to 297/10
5 
p-y., and among females from 229 
to 156/10
5
p-y.. The majority of age groups experienced incidence decline. 
Nevertheless, incidence rates increased among men aged 30-39 and ≥90 years, as 
well as women aged 30-39, 40-49, and ≥90 years. In addition, after an initial period 
of incidence decline from 1978 to 1996, MI incidence rates increased among men 
aged 40-49 and women aged 50-59 years from 1996 through 2012. One-year case 
fatality for MI patients decreased significantly among men from 50% to 9%, and 
among women from 53% to 15% comparing the year 1978 to 2012.  
 
In Study II: one-year mortality for NSTEMI patients with 0-vessel, atherosclerosis, 
1-vessel, 2-vessel, and 3-vessel disease was 3.7%, 5.7%, 2.5%, 4.8 %, and 11.5%, 
respectively. Non-diabetic NSTEMI patients in the 0-vessel group had a higher risk 
of mortality than those in the 1-vessel group (multi-variable adjusted (HR:1.59; 
95% CI:1.21-2.02; P<0.001), while diabetic patients had no significant difference in 
mortality risk. In addition, the 0-vessel group had a higher risk of heart failure 
(HR:1.61; 95% CI:1.39-1.88; P <0.001), a non-significant different risk of stroke, 
and a lower risk of recurrent MI (HR:0.55; 95% CI:0.39-0.77; P <0.001) compared 
with the 1-vessel group. Patients in the atherosclerosis group had a higher risk of 
mortality and heart failure, and a non-significant difference in the risk of recurrent 
XI 
MI and stroke compared with patients in the 1-vessel group. Moreover, both 
diabetic and non-diabetic atherosclerosis patients compared with the 2-vessel group 
had a non-significant difference in the risk of mortality (HR:1.63; 95% CI:0.85-
3.13; P 0.14; HR:1.45; 95% CI:0.99-2.13; P 0.06, respectively), a non-significant 
difference in the risk of heart failure and stroke, but a lower risk of recurrent MI 
(HR:0.55; 95% CI:0.36-0.84; P 0.005). In addition, diabetic patients in the 0-vessel 
group had a lower risk of mortality compared with the atherosclerosis group 
(HR:0.16; 95% CI:0.05-0.51; P 0.002), but this difference was not found if patients 
had no diabetes mellitus. The atherosclerosis group had a higher risk of recurrent 
MI than the 0-vessel group (HR:1.7; 95% CI:1.05-2.89; P 0.03), and these two 
groups had similar long-term heart failure and stroke risks. 
In study III: 124 out of 534 patients had an elevated cardiac troponin level in at 
least one blood sample. Among these 124, 4 patients (3.2 %) had troponin levels 
elevated solely in the third sample. All 4 patients were eligible to be referred for 
urgent or acute coronary angiography due to their risk profile and/or ECG changes, 
irrespective of the results of the third sample. 275 patients had to extend their 
hospital stay by half a day on average waiting for the results of the third sample, 
thus the incremental costs of the third blood sample was: [534 patients x Euro 12 
per troponin analysis] + [275 patients x 0.5 day x Euro 1,550] = Euro 219,533. 
Approximately 1,400 patients with suspected non-ST-segment elevation acute 
coronary syndrome are admitted to our department per year. Thus, the total cost per 
year is: (1,400/534) x Euro 219,533 = Euro 575,555.  
 
Conclusion  
Myocardial infarction continues to constitute a burden on the health care system, 
even though incidence rates have decreased and prognosis has improved during the 
last few decades. There is, however, a worrying increase in incidence rates 
observed in this study among women under 60 years, men under 50 years, and 
patients over 90 years. This should be addressed with further studies to confirm and 
understand this trend, which might lead to changes in preventive measures focusing 
on these age groups (study I). The prognosis of NSTEMI patients with zero-vessel 
disease is not better than that of patients with one-vessel disease, and the out-come 
of NSTEMI patients with diffuse atherosclerosis is not better than two-vessel 
disease. Furthermore, the outcome of diffuse atherosclerosis patients is worse than 
those with zero-vessel disease. These findings call for considering these two groups 
(zero-vessel disease and diffuse atherosclerosis) separately in the future research 
and need further studies to explore the mechanisms causing myocardial injury and 
the optimal management of these NSTEMI subgroups (study II). The third blood 
sample of cardiac troponin is not cost-effective in the management of patients 
admitted with a suspected acute coronary syndrome, and leads to increased hospital 
stays and health care costs (study III). 
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XIII 
DANSK RESUME 
Baggrund  
Denne Ph.d.-afhandling adresserer tre problemstillinger med relevans for 
myokardieinfarkt (MI): (1) Mortaliteten, som er relateret til iskæmisk 
hjertesygdom, er faldet signifikant i de vestlige lande. Ændringer i risikofaktorer og 
behandlingsstrategier kunne have haft en effekt på incidensen og mortaliteten. Men 
ændringer i risikofaktorer har ikke været ens i alle køns- og aldersgrupper. Derfor 
skal ændringer i incidens og mortalitet over tid undersøges inden for forskellige 
alder- og kønsgrupper. (2) Der er veletableret medicinske samt 
revaskularisationsanbefalinger for MI patienter med stenose i deres koronararterier. 
Imidlertid er der mange patienter med MI uden signifikant stenoser. Disse patienter 
modtager ikke den samme medicinske behandling som dem med signifikante 
stenoser. Derfor skal prognosen af MI patienter uden signifikante stenoser nærmere 
karakteriseres. (3) Omkostningerne for indlæggelser på grund af MI og observation 
for MI udgør en stor del af det  samlede sundhedsbudget. Ét af aspekterne er rutine 
indsamling af tre blodprøver  med henblik på analyse af troponin, før MI kan 
afkræftes og patienten kan forsvarligt udskrives. Denne rutine praksis medfører til 
øget indlæggelsestid og dermed øgede omkostninger. Derfor er en Cost-effective 
analyse ønskelig for denne praksis.  
Formål 
Formålet for denne afhandling er dermed at undersøge de ovennævnte uløste 
aspekter af  MI forekomst, prognose, samt udgifter til sundhedssystemet. 
1. At undersøge tidsmæssige tendenser i myokardieinfarkt forekomst og dødelighed 
afhængig af alder og køn over en 35-årig periode (1978-2012) i Danmark. 
2. At undersøge en langsigtet prognose af patienter med non-ST-segment elevation 
myokardieinfarkt fordelt over 5 grupper afhængige af kranspulsåren patologi på 
koronarangiografi. 
3. At analysere cost-effectiveness af den tredje blodprøve for at måle troponin hos 
patienter indlagt på grund af mistanke om non-ST-segment elevation akut koronart 
syndrom. 
Metoder 
 Studie I og II er historiske prospektive studier, hvor data er indsamlet fra 
forskellige danske registre.  
I studie I patienter i alderen ≥30 år indlagt med førstegangs MI på alle danske 
sygehuse i årene 1978-2012 (n = 316,790) var inkluderet. 
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Studie II omfatter 8.889 patienter, indlagt for førstegangs non-ST-segment 
elevation myokardieinfarkt (NSTEMI) på sygehuse i det vestlige Danmark, som 
gennemgik koronarangiografi inden for 30 dage, i løbet af 2000-2011. Patienterne 
er klassificeret som: nul karsygdom (0-kar gruppe) indikere angiografisk normale 
koronararterier eller minimal aterosklerose; diffus aterosklerose uden stenose ≥ 
50% (aterosklerose gruppe), 1 karsygdom (1-kar gruppe), 2 karsygdom (2-kar 
gruppe), og 3 karsygdom (3-kar gruppe) med stenose ≥50%. Opfølgningsperiode: 
13 år (median 4,5) til 31-12-2012.  
Studie III er en analyse af omkostningerne versus effektiviteten af den tredje 
blodprøve af kardial troponin. Studiet inkluderede 534 konsekvative patienter som 
var indlagt på mistanke om akut koronart syndrome uden ST-elevation ved EKG på 
Aalborg Universitetshospital fra mars til november 2003.  
Udgifterne beregnet ud fra udgifterne til troponinanalyse (Euro 12) samt et-døgns 
ophold på kardiologisk afdeling med overvågning, som skønnes at være Eruo 1.550. 
Det forlængede ophold på grund af den tredje blodprøve er estimeret til at være 0,5 
dag i gennemsnit. Effektiviteten er estimeret udfra, hvordan den tredje troponin 
blodprøve påvirker patienternes undersøgelse- og behandlingsplan.  
 
Resultater  
Studie I: Førstegangs MI incidens pr 100.000 person-år (/ 10
5
 p-y.) faldt betydeligt 
blandt mænd fra 500 til 297/10
5
 p-y. og blandt kvinder fra 229 til 156 / 10
5
p-y. De 
fleste af aldersgrupperne oplevede forekomst tilbagegang. Ikke desto mindre er 
forekomsten steget blandt mænd i alderen 30-39 og ≥90 år, samt kvinder i alderen 
30-39, 40-49, og ≥90 år. Hertil kommer, at MI forekomsten, efter en indledende 
periode, hvor incidensen faldt fra 1978 til 1996, steg blandt mænd i alderen 40-49 
og kvinder i alderen 50-59 år fra 1996 til 2012. 
1-års mortalitet efter første MI faldt markant blandt mænd fra 50% til 9%, og blandt 
kvinder fra 53% til 15% sammenlignet år 1978 med 2012. 
 
Studie II: 1-års mortalitet for NSTEMI patienter med 0-karsydomme, aterosklerose, 
1-karsygdom, 2-karsygdom, og 3-karsygdomme var henholdsvis 3,7%, 5,7%, 2,5%, 
4,8% og 11,5%. NSTEMI patienter uden diabetes, som har 0-karsygdom, havde en 
højere risiko for dødelighed end 1-karsygdoms gruppen (multi-variable justeret 
HR:1,59; 95% CI:1,21-2,02; P <0,001), mens diabetikere havde en ikke signifikant 
forskel på dødelighedens risiko. Desuden havde den gruppe med 0-karsydom en 
højere risiko for hjertesvigt (HR:1,61; 95% CI:1,39-1,88; P <0,001), en ikke 
signifikant anderledes risiko for slagtilfælde, og en lavere risiko for 
tilbagevendende MI (HR:0,55; 95% CI:0,39-0,77; P <0,001) sammenlignet med 1-
karsygdoms gruppen; mens patienter med aterosklerose  havde en højere risiko for 
dødelighed og hjertesvigt, og en ikke signifikant anderledes risiko for 
tilbagevendende MI og slagtilfælde sammenlignet med patienter med 1-karsygdom. 
Desuden havde både diabetiske og ikke-diabetiske aterosklerose patienter 
XV 
sammenlignet med 2-karsygdom en ikke signifikant anderledes risiko for 
dødelighed (henholdsvis HR:1,63; 95% CI:0,85-3,13; P 0,14, HR:1,45; 95% 
CI:0,99-2,13; P 0,06,). Desuden havde de heller ikke en signifikant anderledes 
risiko for hjertesvigt og slagtilfælde, men en lavere risiko for tilbagevendende MI 
(HR:0,55; 95% CI:0,36-0,84; P 0,005). Endvidere havde diabetes patienter med 0-
karsydom en lavere risiko for dødelighed end patienter med aterosklerose (HR:0,16; 
95% CI:0,05-0,51; P 0,002), men lignende risiko, hvis ikke de var diabetikere. 
Patienter i aterosklerose gruppen havde en højere risiko for tilbagevendende MI end 
patienter i 0-karsydom gruppen (HR:1,7; 95% CI:1,05-2,89; P 0,03), og disse to 
grupper var ens med hensyn til de langsigtet hjertesvigt og slagtilfælde risici. 
Studie III: 124 ud af 534 patienter havde et forhøjet kardial troponin i mindst én 
blodprøve. Blandt disse 124, 4 patienter (3,2%) havde forhøjet troponin alene i den 
tredje prøve. Alle disse 4 patienter var berettiget til at blive henvist til subakut eller 
akut koronar angiografi grundet deres risikoprofil og/eller EKG-forandringer, 
uanset resultatet af den tredje prøve. 275 patienter fik forlænget deres 
hospitalsophold en halv dag i gennemsnit, menes de ventede på resultaterne af den 
tredje prøve, således var de ekstra omkostninger forbundet med den tredje 
blodprøve: [534 patienter x Euro 12 per troponin analyse] + [275 patienter x 0,5 dag 
x Euro 1.550] = Euro 219.533. Cirka 1.400 patienter er indlagt på vores afdeling om 
året med observation for non-ST-elevation akut koronart syndrom. Således er de 
samlede omkostninger per år: (1400/534) x Euro 219.533 = Euro 575.555. 
 
Konklusion  
Myokardieinfarkt fortsætter med at udgøre en udfordring for sundhedssystemet, 
selvom forekomsten er faldet og prognosen forbedret i løbet af de sidste par årtier. 
En foruroligende stigning i forekomsten af myokardieinfarkt er blevet  observeret i 
denne undersøgelse blandt kvinder under 60 år, mænd under 50 år, og patienter 
over 90 år. Dette bør undersøges nærmere for at bekræfte og forstå denne tendens 
som kan føre til ændring i forebyggende foranstaltninger, der fokuserer på disse 
aldersgrupper (studie I). Prognosen for NSTEMI patienter med nul-karsydom er 
ikke bedre end for patienter med 1-karsygdom, og prognosen af NSTEMI patienter 
med diffus aterosklerose er ikke bedre end 2- kar-sygdom. Desuden er prognosen 
for aterosklerose patienter værre end for patienter med nul-karsygdom. Disse 
resultater appellerer for at betragte nul-karsygdom og diffus aterosklerose separat i 
fremtidig forskning samt kræver yderligere undersøgelser af mekanismerne af 
myokardieskade samt den optimale behandling af disse NSTEMI undergrupper 
(studie II). Den tredje troponinblodprøve er ikke cost-effective i behandlingen af 
patienter indlagt med et formodet akut koronart syndrom, og fører til en unødvendig 
forlængelse af hospitalsophold og dermed forøgede sundhedsudgifter (studie III).
XIX 
ABBREVIATIONS: 
ATC: Anatomical Therapeutic Chemical 
CI: Confidence Interval 
EF: Ejection Fraction 
HF: Heart Failure 
ICD: International Classification of Diseases 
MI:  Myocardial Infarction 
NSTE-ACS: Non-ST-segment Elevation Acute Coronary Syndrome 
NSTEMI: Non-ST-segment Elevation Myocardial Infarction 
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1. INTRODUCTION 
1.1 Myocardial infarction definition and significance  
Death rates attributed to Ischemic Heart Disease (IHD) declined consistently 
over the last 50 years.
1
 Nevertheless, IHD is still the most common cause of death 
in the world accounting for 7.4 million deaths in 2012.
2
 In Europe it is responsible 
for 888,194 deaths among men and 915,548 deaths among women comprising 20% 
and 22% of all deaths, respectively,
3
 and in the U.S. it accounts for one sixth of all 
deaths.
4
 Therefore, it remains a necessity to evaluate the efforts of prevention and 
treatment of Myocardial Infarction (MI). 
MI is defined pathologically as myocardial cell death due to prolonged ischemia, 
which is accepted to be the result of thrombosis caused by plaque rupture or erosion 
in coronary arteries with significant stenosis ≥50%.5–7 However, there are many 
reports of MI without significant coronary artery disease with either normal 
coronary arteries or atherosclerosis with stenosis <50% which does not require 
revascularization procedure in term of per coetaneous intervention or coronary 
bypass operation.
8–10
 
The definition of the clinical syndrome designated as MI  has been refined several 
times over the last few decades; from being based on classical symptoms of 
ischemic chest pain and ECG changes, to be based on biomarkers of cardiac 
necrosis, which can detect small injury to the myocardium.
11
 These biomarkers 
have developed over the years from the non specific serum glutamic oxaloacetic 
transaminase and lactate dehydrogenase to creatinin kinase with its more cardiac 
specific isofrom (CK-MB), and the more sensitive and specific cardiac troponin. 
The assay of the later has furthermore developed through the recent years to be a 
high sensitive troponin I & T. The Third Universal definition of Myocardial 
Infarction is therefore based on rise/or fall in cardiac biomarkers (preferably 
troponin) accompanied by either typical symptoms, pathological Q waves, ST-
segment elevation or depression, or imaging evidence of new loss of viable 
myocardium or new regional wall motion abnormality.
12
 
Clinically and for the sake of acute management decisions regarding reperfusion 
therapy, MI is classified according to ECG changes, in the presence of ischemic 
symptoms, into ST-segment elevation MI (STEMI) and non-ST-segment elevation 
MI (NSTEMI).  
Modifiable traditional risk factors for acquiring IHD such as hypertension, 
hypercholesterolemia, diabetes mellitus, obesity, smoking, and physical inactivity 
have changed in society over the last few decades. On the one hand, some risk 
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factors have declined like cigarette smoking, hypercholesterolemia and 
hypertension because of improved awareness and treatment of these conditions;
1,13-
14
 On the other hand, obesity and diabetes mellitus have increased in society, 
15–17
 
especially among the younger populations.
18–20
  
1.2. Temporal changes in incidence rate of myocardial infraction 
over time  
Reports on the incidence rate of MI which used data collected before the year 2000 
were contradictory; some of which reported a stable or increased incidence, 
21–24
 
while others reported a decline in incidence rates. 
25–29
 However, studies extended 
to more recent years show a decline in MI incidence rates.
30–33
   
These studies, however, did not examine in details the changing incidence among 
different age groups for both genders. The change in risk factors for MI, which 
disproportionally affected different age groups, as well as, the change of MI 
definition might have altered the incidence of MI over the last few decades 
differently across age groups for both genders. This information could be crucial to 
focus future preventive and treatment efforts if the change in incidence is age 
and/or gender specific. Moreover, the use of evidence based treatment after MI 
including both reperfusion therapy and medical therapy for secondary prevention 
have been increasing over time,
30
 which might have led to a decrease in one-year 
mortality rates after MI. 
1.3. Non-ST-segement elevation myocardial infarction with non-
obstructive coronary artery disease 
As previously mentioned, NSTEMI can be associated with non-obstructive 
coronary artery disease. There are many proposed mechanisms of myocardial injury 
among these patients; some of these mechanisms involve ischemia as the major 
cause,
34–36
 including disruption in plaques which did not lead to significant stenosis 
on the angiography because the clot might have dissolved before the angiography 
was done.
37
 Other mechanisms of myocardial injury in these patients are not related 
to ischemia.
9
 
Previous studies suggested that factors predicting non-obstructive coronary arteries 
among MI patients are: female gender, younger age, renal insufficiency, and lack of 
smoking or diabetes.
38–41
 
NSTEMI patients without obstructive coronary artery disease are less likely to 
receive recommended medical treatment after MI,
42
 and more likely to discontinue 
double platelet inhibitors than patients with NSTEMI and obstructive coronary 
artery disease.
39,43
 This difference in management can affect their prognosis. 
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Some studies suggested that NSTEMI patients without significant stenosis have a 
benign prognosis, with a lower one-year mortality risk,
44
 and less in-hospital 
mortality, re-infarction, congestive heart failure, or cardiogenic shock than 
NSTEMI patients with obstructive coronary artery disease.
38
 Nevertheless, there are 
other reports both from pooled data of large international studies 
45
 and from real-
world observations 
39
 which doubted the good prognosis of these patients. These 
studies illustrated a substantial risk among these patients with higher risk of one-
year all cause mortality,
41
 or no difference in combined major cardiovascular 
adverse events comparing non-obstructive to obstructive coronary artery disease.
39
 
These studies, however, are either from controlled trials
45
 with a small sample 
size,
43
 or with a short duration of follow-up.
38
 
In addition, most of these prognostic studies divided NSTEMI patients into 
obstructive versus non-obstructive coronary artery disease, but there are only a few 
studies which differentiated patients with non-obstructive coronary artery disease 
into angiographically normal coronary arteries, and atherosclerosis without stenosis 
>50% subgroups;
45
 or divided patients with obstructive coronary artery disease 
according to the severity of the disease defined by the number of coronary vessels 
involved which is an important prognostic factor.
44
 This subgroup distinction is of 
importance because patients with angiographically normal or near-normal coronary 
arteries might have different mechanisms of myocardial injury and by that represent 
another patient group than those with moderate diffuse atherosclerosis without 
significant stenosis. Thus their prognosis and potential management might differ 
accordingly.  
1.4. Cost-Effectiveness of cardiac troponin in the management 
of suspected non-ST-segment elevation acute coronary 
syndrome 
Health care costs attributed to admissions for both MI and suspected acute coronary 
syndrome are increasing,
46,47
 and a strategy that can reduce the length of stay in 
hospital is highly desirable. 
As part of the standard clinical care for patients admitted with a suspected acute 
coronary syndrome, three or more serial blood samples are drawn to determine 
troponin level changes with 6-12 hour intervals during the observation period. This 
strategy has been adopted over a long time.
48,49
 
Nonetheless, taking into consideration the kinetics of  cardiac troponin that troponin 
level increases within 3-6 hours from the onset of symptoms,
50–52
 it would be 
sufficient to draw two blood samples from the patient to detect a change in cardiac 
troponin level 6-9 hours apart. The strategy of drawing more than two samples costs 
at least an extra 12-24 hour length of stay in the hospital before the diagnosis of 
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NSTEMI can be ruled out, and before the patient can be safely discharged. The 
cost-effectiveness of this strategy has not yet been evaluated. 
Overall, there are many aspects of MI diagnosis, prognosis and health care costs yet 
to be illuminated. The aforementioned observations resulted in three main aims of 
this thesis in order to answer some unresolved questions. 
 
29 
2. HYPOTHESES AND AIMS 
The global aim of this dissertation is to contribute to the knowledge surrounding 
myocardial infarction incidence, prognosis, and health care costs. 
Hypotheses: 
1- The temporal changes in incidence rates of MI over the last few decades are 
unequal among all age groups for both genders, and mortality following MI has 
decreased over the last few decades. 
2- The long-term prognosis of NSTEMI patients with angiographically normal 
coronary arteries is different from those with atherosclerosis without stenosis 
>50%, and the prognosis of both these two groups is better than NSTEMI patients 
with obstructive coronary artery disease of different degrees. 
3- The diagnostic value of the third blood sample to measure cardiac troponin levels 
in patients under observation for suspected acute coronary syndrome does not 
justify the cost of extended length of stay in the hospital.  
These hypotheses were formed into the following aims for the three studies: 
1. To examine temporal trends in myocardial infarction incidence and one-year case 
fatality according to age and gender in Denmark over a 35-year period (1978-2012). 
2. To investigate the long-term outcome of patients with non-ST-segment elevation 
myocardial infarction according to coronary artery pathology on the angiography.  
3. To analyse the cost-effectiveness of the third blood sample to measure troponin 
in patients admitted with a suspected non-ST-segment elevation acute coronary 
syndrome. 
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3. METHODS AND MATERIALS 
3.1. Study design 
Study I and II were historical prospective cohort studies based on data collected 
from the following Danish registries: the Civil Registration System and the Danish 
National Patient Register (study I&II), the National Prescription Register and the 
Western Denmark Heart Registry (study II). Study III was a cross sectional study. 
3.2. The registries 
All residents in Denmark have a unique identification number which facilitate the 
linkage of information from various registers on person-level. 
The Civil Registration System contains information on date of birth, sex, and date 
of death of all Danish citizens at birth and residents upon immigration.
53
 
The Danish National Patient Register has collected data on all non-psychiatric 
admissions to Danish hospitals since 1977, which become more complete in 1978, 
and out-patients visits since 1995. This data includes discharge diagnosis using the 
International Classification of Diseases version 8 (ICD-8) from the year 1977 to 
1994, and ICD-10 thereafter. The register is a valuable tool for research.
54,55
 
The National Prescription Register holds information on prescriptions like date of 
purchase, size of package, number of package, dosage, and drug code according to 
the international Anatomical Therapeutic Chemical (ATC) classification system.
56
 
The Western Denmark Heart Registry is a clinical database. It was launched on 1 
January 1999 to monitor and improve the quality of cardiac interventions in western 
Denmark (3,071,110 persons, 54,3% of Denmark's population).
57
 This database 
collects detailed patients and procedures data for all interventions performed, and is 
a validated valuable research source.
58
 
3.3. Study population 
Study I: 
Consecutive patients aged 30 year and older admitted with first time MI to Danish 
hospitals during the period January 1
st
, 1978 to December 31
st
, 2012 were included 
in the study. Figure 1 shows the inclusion process. Final study population was 
316,790 patients. Study period was divided into seven periods of five years. Each 
period started with January 1
s
 of the first year and ended on December 31
st
 of the 
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last year of the period. Patients were then divided into male and female genders and 
within each gender; patients were divided into seven age groups of 10-year 
intervals.  
Study II: 
This study included consecutive patients admitted to hospitals in the western part of 
Denmark with a first time NSTEMI, who underwent coronary angiography within 
30 days of their admission, during the period January 1
st
, 2000 to August 31
st
, 2011. 
Exclusion criteria: unavailable description of coronary artery pathology, previous 
MI, previous revascularization procedure with either per coetaneous intervention or 
coronary bypass operation, and known heart failure. The final study population was 
8,889 patients. The study population was divided into five subgroups according to 
angiographic description of the degree of stenois of the coronary arteries as: zero-
vessel disease (0-vessel group) indicating angiographically normal coronary arteries 
or very mild atherosclerosis; diffuse atherosclerosis (atherosclerosis group) 
indicating moderate focal or diffuse atherosclerosis with stenosis <50%; one-vessel 
disease with stenosis ≥50% (1-vessel group); two-vessel disease with stenosis 
≥50% (2-vessel group); or three-vessel disease with stenosis ≥50% (3-vessel 
group). Left main with stenosis ≥50% was considered as two-vessel disease if the 
right coronary artery was without significant stenosis, and three-vessel disease if the 
right coronary artery was hypoplastic or with significant stenosis ≥50%. 
 
Study III: 
534 consecutive patients who were admitted with chest pain and suspected non-ST-
segment elevation acute coronary syndrome at Aalborg University Hospital 
between March and November 2003 were included.  
All patients were subject to the following routine diagnostic procedures: Clinical 
history and examination, chest x-ray, 12 leads ECG, and laboratory assessment 
(electrolytes, hepatic and renal status, lipids, screening for infection in urine and 
blood, as well as cardiac biomarkers). 
Blood sampling was scheduled according to the department’s routine procedure 
with blood samples for cardiac troponin T (cTnT) obtained on arrival, after 6-9 
hours, and after 12-24 hours from admission. All patients had three blood samples 
taken to exclude/verify acute MI diagnosis. 
cTnT was determined from serum samples on Elecsys 2010 (Roche Diagnostics, 
Mannheim, Germany). For cTnT (4
th
 generation assay), the lowest concentration 
exhibiting imprecision coefficient of variation (CV) < 10 % was 0.03 µg/L.
59
 
All patients were transferred to the department of cardiology with monitoring with a 
standard treatment regimen for patients suspected of non-ST-elevation acute 
coronary syndrome according to the guidelines at the time of the study.
52
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3.4. Study definitions 
Definition of MI: 
The discharge diagnosis of myocardial infarction in Danish Patient Register was 
validated previously and found reliable with positive predictive value of 92-93%
60,61
 
In study I, first time MI was defined as the first hospital admission with MI 
diagnosis recorded in the Danish National Patient Register. We used ICD-8 code 
410 (from 1978 to 1994) and ICD-10 code I21 (from 1994 to 2012). Only primary 
discharge diagnoses were used. As the register started in 1977, we could not 
confirm that patients in the early years of the study did not have a MI diagnosis 
before 1977, therefore a sensitivity analysis was performed using all MI (both first 
time and recurrent MI). The results did not diverge significantly from first MI 
analysis.  
 
In Study II, first time NSTEMI was defined as first hospital admission registered in 
the Patient Register with a primary discharge diagnosis using ICD-10 code: I21.4 
(NSTEMI) or I21.9 (acute MI, unspecified), the latter was considered as NSTEMI 
if the diagnosis of NSTEMI was confirmed from the Western Denmark Heart 
Registry. A period of 6 years from 1994-2000 was used to ensure that patients did 
not acquire MI previously.  
 
A recurrent MI as an outcome in study II was defined as any hospital admission 
with a MI diagnosis using ICD-10 code: I21. We performed a program that merged 
all related admissions in one admission to avoid the transfer of patients between 
hospitals being misclassified as a new admission with recurrent MI. We also used a 
safety period of 5 days after discharge day where no MI diagnosis can be taken into 
consideration. Moreover, we performed a sensitivity analysis were we considered 
recurrent MI only if it occurs ≥30 days from the first MI.  
 
In study III,  Patients were classified as having acute MI according to the universal 
definition of MI used at the time of the study.
62
 These included detection of rise 
and/or fall of cardiac troponin, together with signs indicative of ischemia (clinical 
symptoms, ECG changes, or imaging evidence of new loss of viable myocardium). 
Troponin level above the 99
th
 percentile of the Upper Reference Limit given 
coefficient of variation <10% was consider diagnostic, and for fourth generation 
cTnT, this level was >0.03 µg/L. 
Definition of heart failure (HF): 
In Study I, one-year heart failure outcome defined as any hospital contact (either 
admission or out-patient visit) using ICD-8 code 4270, 4271 or 428 (1978–1994) 
and ICD-10 code I50 or I255 from 1994 in Danish Patient Register. 
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In study II, heart failure outcome after first NSTEMI defined as either first hospital 
contact with heart failure diagnosis using ICD-10 code: I509 or I255, or first time 
purchase of prescription of loop diuretics after the index admission for first 
NSTEMI, using ATC code: C03C in the Danish National Prescription Register. The 
prescription of loop diuretics as proxy for heart failure diagnosis was used because 
the sensitivity of heart failure diagnosis in Patient Register was proven to be 29% 
but the specificity was 99%.
63
 Moreover patients with a loop diuretics prescription 
or heart failure diagnosis prior to NSTEMI were excluded from the study, thus the 
most likely indication for loop diuretics after MI is heart failure. This approach 
considered acceptable as the majority of heart failure patients have previously been 
reported to use loop diuretics,
64,65
 and the same approach was used in a previously 
published report.
66
 Moreover, in Denmark it is very rare to use loop diuretics for 
hypertension but mostly thiazide diuretics which are not included in our analysis. 
Definition of stroke: 
In Study II, stroke event after first NSTEMI was defined as either hemorrhagic or 
ischemic stroke using ICD-10 code: I63, I62, I61, or I64. Patients, who had a stroke 
diagnosis before their NSTEMI diagnosis, were labeled as known with previous 
stroke and were not included in stroke outcome analysis after MI. 
3.5. Health care cost assessment 
In Study III, the total cost attributed to the third cTnT sample, was calculated taking 
into account:  
1. The cost of a cTnT analysis (Euro 12). 
 2. The cost of an extended length of stay in the department of cardiology with 
monitoring solely due to the third troponin sample (on average 0.5 day per patient). 
The system which calculates the cost of each admission to Danish hospitals is a 
diagnosis-related system, which assigns Euro 1,550 to the diagnosis: observation 
due to a suspected acute coronary syndrome. This is calculated from an average 
admission of one day for those patients.   
3. Approximately 1,400 patients are admitted to the department of cardiology at 
Aalborg university hospital per year with a suspected non-ST-elevation acute 
coronary syndrome. 
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3.6. Outcomes and follow up duration 
In Study I, the primary outcomes were incidence rates of first time MI and one-year 
all-cause case fatality after first MI. Follow-up duration: 365.25 days from the 
admission day.  
 
In Study II, the primary outcomes were all-cause mortality, recurrent MI, heart 
failure, and stroke after first admission for NSTEMI. Follow-up duration: median 
4.5 years, inter quartile range (1.3 (2.6-6.8) 13) years. 
 
In Study III, the outcome was the estimated cost attributed to the third blood sample 
of troponin versus the impact of the third sample results on clinical decisions of 
patients' management.  
 
3.7. Statistical analysis 
Continuous variables were presented as a mean with standard deviation or median 
with inter quartile range, and the difference between multiple groups was tested 
using a parametric test one-way analysis of variance (ANOVA) as data was 
normally distributed with a large sample size. 
Categorical variables were presented as frequencies and percentages, and compared 
by chi-square test.  
In Study I, an incidence density rate (person-time incidence rate) was calculated as 
number of new cases per 100.000 person-years. One-year mortality was assessed 
both as person-time mortality rate in population per 100,000 person-years within 
one year of admission for a first time MI, and as one-year case fatality proportion 
from first MI patients.  
Population was stratified according to gender and age, and incidence and mortality 
rates were calculated for each stratum. 
Rate ratio was calculated using poisson regression model, which is a type of general 
linear regression model. The assumption of independency was fulfilled. Age, sex, 
and time period were included in the model as covariates. Male gender, age group 
70-79 year, and period 1978-1982 were used as reference groups for comparison 
because these groups were with the largest number of cases.  
In Study II, Aalan-Neilson estimator for cumulative incidence was used taking into 
account death as a competing risk for other outcomes than mortality. 
To estimate Hazard Ratio, Cox proportional hazard ratio was applied with the date 
of admission for first NSTEMI (date of entry into the study) as the time scale. 
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Model assumption of proportional hazards was examined with cumulative hazard 
plot and tested based on Schoenfeld residuals and found valid. The model was 
adjusted for age, sex, hypertension, diabetes, smoking, overweight (defined as body 
mass index ≥25, and renal insufficiency (defined as estimated glumerular filtration 
rate <60 ml/min/1.73m
2 
according to MDRD equation). These parameters 
condemned as confounders because they were risk factors for the outcomes of 
interest, and they were associated with the exposure but were not located in the 
causal pathway between the exposure and outcome. Cox model was primarily 
performed using one-vessel disease group as a reference group because this group 
was with the largest number of cases, and because it is of a primary interest to 
compare the two sub-groups of non-obstructive coronary artery disease to this 
group. Cox model was performed afterward with diffuse atherosclerosis as the 
reference group, then zero-vessel disease, two-vessel disease, and lastly three-vessel 
disease as the reference group in order to get most possible details on the 
differences among all groups. 
Ejection fraction (EF) was not used as a confounder because of too many missing 
observations (55% missing), but an additional analysis was performed for the 
subgroup of patients with available measurement of EF. 
Effect modification was tested for several clinically relevant variables; namely age, 
sex, smoking, overweight, hypertension, diabetes mellitus, and renal insufficiency. 
An evidence of diabetes mellitus being an effect modifier of coronary pathology 
subgroups on the mortality outcome was found. Therefore two types of analysis 
approach were performed; one using a designed variable which combined coronary 
pathology subgroup with diabetes status, and the other was done by applying the 
model with and without diabetes. In the designed variable approach, one-vessel 
disease without diabetes group was used as a reference group for comparison. No 
major differences were found between these two approaches, thus the results were 
presented separately for patients with and without diabetes. 
Linearity for the continuous variable age was tested using likelihood ratio test, and 
we found that there is strong evidence against the absence of linear effect of age 
categories (P < 0.002).We decided therefore to use age as a continuous variable.  
P value of <0.05 (two-tailed) was considered as strong evidence against the null 
hypothesis and thus a sign of statistical significance. Results were reported with 
95% confidence interval (CI). 
Management of data and statistical analyses were run in SAS 9.2/9.4 (SAS Institute 
Inc., Gary, NC, USA) and R 3.0.2. (R Core Team (2013). R: A language and 
environment for statistical computing. R Foundation for Statistical Computing.  
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3.8. Ethical considerations 
Register–based studies do not require ethical approval in Denmark. Study I&II were 
approved by the Danish Data Protection Agency (RE: 2007-58-0015, int. ref.: 
GEH-2014-014 I-Suite no: 02732) and (RE: 2008-58-0028, int.ref.: 2015-50). 
Study III was performed in accordance with the revised Helsinki Declaration, 
approved by the local scientific ethical committee, and participants gave informed 
written consent. 
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421,512 comprised all MI patients in 
Denmark from 1978-2012
4,265 patients aged under 
30 year
100,294 patients admitted 
for recurrent MI
321,218 patients admitted for first 
MI from 1978-2012
316,953 patients aged 30 years or 
older with first MI
316,790 patients comprised study 
population with first MI and 
available mortality status after 1 year
163 patients emigrated within 
one year after first MI
 
 
Figure 1: Inclusion process in Study I. 
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4. RESULTS 
4.1. Study I: 
Incidence and outcome of first myocardial infarction according 
to gender and age in Denmark over a 35-year period (1978-2012) 
The objective of this study was to examine temporal changes in first MI incidence 
rates and one-year mortality in various age groups for both genders in Denmark 
over a 35-year period. 
 
Methods: From 1978 through 2012, there were 316,953 hospitalizations for first 
time MI in patients aged 30 years or older. 163 patients were excluded from the 
study due to emigration, thus study population was 316,790 patients.  
 
Results: During the first 25 years of the study period, the male proportion of first 
MI patients fell from 66% to 62% (P<0.001), but it increased in the remainder time 
to 64% (P<0.001). The mean age of patients at diagnosis increased gradually from 
68.6 to 69.1 years (P<0.001) during the first 30 years, but it declined thereafter to 
68.2 years (P<0.001). The length of hospital stay decreased consistently and 
significantly during the study period. 
 
For all patients, first MI incidence per 100.000 person-years (/10
5 
p-y.) decreased 
significantly from 359/10
5
 p-y. in 1978 to 225/10
5
 p-y. in 2012, this was a 37% 
decline in incidence rates. Incidence rate decrease was more pronounced in males, 
with a decline from 500 to 297/10
5
p-y. (41% reduction), than in females in which 
MI incidence rate was reduced from 229 to 156/10
5
p-y. comparing 2012 to 1978 
(32% reduction). (Figure 2). 
 
Dividing gender into seven age groups revealed that the greatest reduction in first 
MI incidence rates were observed among males aged 70–79 years from 1460 to 
643/10
5
p-y. (-56%), next came males aged 60–69 (-54%) followed by females aged 
70–79 (-50%). (Figure 3) 
 
On the other hand, males aged 30–39 years as well as females aged 30–39 and 
females aged 40–49 years experienced an increase in incidence rates of MI. A 
similar pattern was found among patients aged ≥90 years for both genders. 
Moreover, a downward trend in incidence rates from 1978 to 1996 was observed 
among males aged 40–49 and females aged 50–59 years, but the incidence rates 
increased in the remainder of the study period.  
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This study showed a remarkable decrease in one-year case fatality from 50% to 9% 
of MI male patients, and from 53% to 15% of MI female patients comparing the 
year 1978 to 2012. This decline was appreciated for all age groups for both genders. 
(Figure 4). 
 
Statistical analysis with poisson model demonstrated that the mortality risk 
decreased through the study period, increased with increasing age, and there was no 
significant difference in mortality risk between genders. (Figure 5) 
 
Conclusions: The incidence rate of first myocardial infarction decreased 
significantly during the period from 1978 to 2012. This decline was observed 
among most age groups for both genders, however an incidence increase was 
observed in men under 50 and women under 60 years, and ≥90 years for both 
genders. One-year case fatality decreased constantly during the study period.  
 
 
 
Figure 2: Incidence rates of first myocardial infarction, one-year mortality, and 
one-year heart failure after first myocardial infarction for both genders.  
MI = myocardial infarction; HF = heart failure. 
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Figure 3: Incidence rates of first myocardial infarction in various age groups in 
males (upper panel) and in females (lower panel). 
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Figure 4: One-year case fatality after first myocardial infarction in various age 
groups in males (upper panel) and in females (lower panel). 
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Figure 5: Rate ratio of one-year mortality after first myocardial infarction. 
Male gender, age group 70–79 years, and period 1978–1982 were used as 
reference groups for comparison. 
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4.2. Study II: 
Long-term outcome of patients with non-ST-segment elevation 
myocardial infarction according to coronary artery pathology on 
the angiography. 
The objective of this study was to examine the long-term outcome of patients with 
non-ST-segment elevation myocardial infarction (NSTEMI) according to their 
coronary artery disease on the angiography.  
Methods: this study recruited 8.889 consecutive patients admitted for first time 
NSTEMI to one of the hospitals in western Denmark, to whom angiography was 
performed within 30 days of admission, during the period 2000 through 2011. 
Patients were classified according to coronary angiography's description of 
coronary pathology into five groups: zero-vessel disease (0-vessel group) indicating 
either angiographically normal coronary arteries or minor focal atherosclerosis, 
diffuse atherosclerosis (atherosclerosis group) indicating moderate focal or diffuse 
atherosclerosis without stenosis ≥50%, one-vessel disease (1-vessel group) with 
stenosis ≥50%, two-vessel disease (2-vessel group) with stenosis ≥50%, and three-
vessel disease (3-vessel group) with stenosis ≥50%. Follow-up period: 13 years 
(median 4.5) to 31/12/2012. 
Results: the prevalence of NSTEMI with non-obstructive coronary artery disease 
(both the 0-vessel and atherosclerosis groups) was 14.5% of all NSTEMI 
population.  
NSTEMI patients in the 0-vessel group had baseline characteristics which were not 
significantly different from those in the 1-vessl group except that they were less 
likely to be current smokers or overweight ((32.4% vs. 42.7, P <0.001; 57.7 vs. 
67.3, P <0.001, respectively), and more likely to be females (59.9% vs. 29.6%, P 
<0.001) (Table 1). Patients in the atherosclerosis group had a non-significantly 
different risk profiles compared with the 2-vessel group, except that they were less 
likely to be overweight (55.6% vs. 66.7, P <0.001), and more likely to be females 
(44.0% vs. 23.3%, P <0.001). On the other hand, patients with atherosclerosis were 
older and more likely to have hypertension and diabetes mellitus but less likely to 
be females compared with 0-vessel patients. 
NSTEMI patients in the 0-vessel group had a 3.6% (95% CI: 2.5-4.8 %) one-year 
all-cause mortality risk and those in the atherosclerosis group had 5.6% (95% CI: 
3.0-8.2 %), while patients in the 1-vessel group had 2.5% (95% CI: 2.0-3.0 %), the 
2-vessel group had 5.0 % (95% CI: 4.0-5.9 %), and the 3-vessel group had 11.5% 
(95% CI:10.1-12.8 %) one-year mortality risk. 
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NSTEMI patients in the 1-vessel group had the lowest unadjusted mortality 
throughout the study period (Figure 6). After multi-variable adjustment, non-
diabetic NSTEMI patients with either 0-vessel disease or diffuse atherosclerosis had 
a higher mortality risk than those with 1-vessel disease (HR:1.59; 95% CI:1.21-
2.02, P<0.001; HR:1.93; 95% CI:1.31-2.83, P<0.001, respectively) (Figure 7). 
Their mortality risk was not significantly different from the 2-vessel and 3-vessel 
groups. In contrast, diabetic NSTEMI patients in the 0-vessel group had a not 
significantly lower mortality risk compared with 1-vessel (HR:0.40; 95% CI:0.14-
1.13, P=0.08), and a significantly lower mortality risk compared with all other 
groups including atherosclerosis group. 
The risk of one-year recurrent MI increased linearly among coronary pathology 
subgroups, thus it was 3.5% (95% CI: 2.4-4.7) in patients in the 0-vessel group, 
6.3% (95% CI: 3.6-9.0) in the atherosclerosis group, 8.3 (95% CI: 7.3-9.2) in the 1-
vessel, 13.5 (95% CI: 12.0-14.9) in the 2-vessel, and 16.8 (95% CI: 15.3-18.4) in 
the 3-vessel group. In a sensitivity analysis taking into consideration only recurrent 
MI 30-365.25 days, these numbers changed to 0.7% (0.2-1.2%) for 0-vessel, 3.3% 
(1.3-5.5%) for atherosclerosis, 2.4% (1.8-2.8%) for 1-vessel, 4.4% (3.6-5.3%) for 2-
vessel, and 7.4% (6.3-8.4%) for the 3-vessel groups, respectively. 
Unadjusted cumulative recurrent MI incidence was highest in the 3-vessel group 
(Figure 6). 
After multi-factorial adjustment, patients with atherosclerosis showed no significant 
difference in recurrent MI risk as compared with the 1-vessel group (HR:0.91; 95% 
CI:0.60-1.39, P=0.66) (Figure 8), and had a lower risk than both the 2-vessel and 
the 3-vessel groups. Patients in the 0-vessel group had the lowest risk of recurrent 
MI in all groups.  
Heart failure risk over the first year after first NSTEMI was 15.9% (13.6-18.2) in 
the 0-vessel group patients, 20.9% (16.3-25.4) in the atherosclerosis patients, 12.0% 
(10.9-13.1) in the 1-vessel patients, 19.2% (17.5-20.9) in the 2-vessel patients, and 
33.6% (31.6-35.6) in the 3-vessel patients. In unadjusted comparison, the 1-vessel 
group had the lowest, and the 3-vessel group had the highest incidence of heart 
failure after first NSTEMI over the study period (Figure 6). 
After multi-variable adjustment, both the 0-vessel and the atherosclerosis groups 
had a higher risk of heart failure compared with the 1-vessel group (HR:1.61; 95% 
CI:1.39-1.88, P<0.001; HR:1.63; 95% CI:1.30-2.06; P<0.001, respectively) (Figure 
8), but showed no significant difference in heart failure risk as compared with the 2-
vessel group. Moreover, the 0-vessel group had a lower risk of heart failure than the 
3-vessel group, while the atherosclerosis group had no difference in heart failure 
risk compared with the 3-vessel group. Heart failure risk was not different between 
the 0-vessel and the atherosclerosis groups. 
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One-year stroke risk was 1.8% in the 0-vessel group, 1.4% in the atherosclerosis 
group, 1.3% in the1-vessel group, 1.8% in the 2-vessel group, and 3.4% in the 3-
vessel group. Incidence of stroke was generally lower than other outcomes, and no 
significant difference between groups was observed from unadjusted cumulative 
stroke incidence (Figure 6). 
After multi-variable adjustment, there was a nominally higher but not significantly 
different risk of stroke comparing the 0-vessel group with both the 1-vessel 
(HR:1.47; 95% CI:0.98-2.20, P=0.06 ) (Figure 8), and the 2-vessel groups 
(HR:1.46; 95% CI:0.95-2.23, P=0.09 ). No difference was observed between the 0-
vessel, atherosclerosis, and 3-vessel groups. No difference was observed comparing 
the atherosclerosis group to all other groups. 
Conclusion: NSTEMI patients with zero-vessel disease or diffuse atherosclerosis 
have a substantial risk of adverse cardiovascular outcomes comparable to those 
with NSTEMI with one- or two-vessel disease patients. NSTEMI patients with 
diffuse atherosclerosis have a higher risk profile and worse outcome than patients 
with angiographically normal coronary arteries or minor focal atherosclerosis.  
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Table 1: Baseline characteristics of patients with non-ST-segment 
elevation myocardial infarction according to coronary artery 
pathology on the angiography. 
 
0VD 
(N=988) 
DA 
(N=302) 
1VD 
(N=3295) 
2VD 
(N=2114) 
3VD 
(N2190) 
P value 
 
       Age (years) 62 {53, 72} 66 {56, 74} 63 {54, 71} 67 {59, 75} 71 {63, 78} < 0.001 
Female gender 585 (59.9) 131 (44.0) 966 (29.6) 489 (23.3) 587 (27.0) < 0.001 
Hypertension 368 (39.2) 143 (49.7) 1290 (41.6) 875 (44.4) 1088 (53.6) < 0.001 
Hyperlipidemia 427 (45.5) 144 (49.5) 1517 (48.9) 1060 (53.6) 1093 (53.9) < 0.001 
Diabetes 106 (11.0) 51 (17.2) 413 (12.9) 342 (16.6) 488 (23.0) < 0.001 
IHD in the family 347 (37.4) 113 (40.1) 1231 (40.5) 765 (39.3) 750 (37.9) 0.3072 
Current smoker 293 (32.4) 100 (36.6) 1303 (42.7) 772 (39.4) 654 (33.0) < 0.001 
Overweight* 463 (57.7) 143 (55.6) 1764 (67.3) 1097 (66.7) 1059 (64.4) < 0.001 
Renal insufficiency** 107 (13.8) 39 (15.4) 353 (13.8) 310 (19.0) 457 (28.0) < 0.001 
EF< 50% 107 (22.1) 37 (25.2) 282 (19.5) 258 (28.7) 427 (42.3) < 0.001 
Previous stroke 36 (3.6) 15 (5.0) 113 (3.4) 111 (5.3) 189 (8.6) < 0.001 
Parameters are presented as numbers (percentage from non-missing data) or median 
(25
th
, 75
th
 percentile). 0VD = zero-vessel disease; DA = diffuse atherosclerosis; 
1VD = one-vessel disease; 2VD = two-vessel disease;   3VD = three-vessel disease; 
IHD = ischemic heart disease; EF = ejection fraction. 
* Overweight was defined as body mass index ≥ 25. 
** Renal insufficiency was defined as estimated glomerular filtration rate < 60 
ml/min/1.73m
2
 using MDRD equation. 
 
 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
48
 
 
Figure 6: Long-term outcomes of NSTEMI patients according to their coronary 
artery pathology on the coronary angiography. 
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Figure 7: Adjusted mortality hazard ratio for NSTEMI patients according to 
coronary artery pathology on coronary angiography. The one-vessel disease group 
was used as a reference group. The model was adjusted for age, sex (female gender 
as reference), hypertension, renal insufficiency (eGFR<60), current smoker status, 
and overweight (BMI ≥ 25).   
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Figure 8: Adjusted hazard ratio for recurrent myocardial infarction, heart failure, 
and stroke in patients with NSTEMI according to coronary artery disease on 
coronary angiography. The one-vessel disease group was used as a reference group 
for comparison. Hazard ratio was adjusted for age, sex (female gender as reference), 
hypertension, diabetes mellitus, renal insufficiency (eGFR<60), current smoker 
status, and overweight (BMI ≥ 25).  
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4.3. Study III: 
 A third troponin T blood sample is not cost-effective in patients 
with suspected non-ST-segment elevation acute coronary 
syndrome. 
In many hospitals, including ours, the standard of care for patients admitted for 
suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) 
includes withdrawing three blood samples to assess the level of cardiac troponin 
with fast intervals during 24 hours admission before myocardial infarction can be 
ruled out. The aim of this study was to evaluate the cost-effectiveness of the third 
blood sample. 
Methods: This study included 543 consecutive patients admitted for suspected 
NSTE-ACS to cardiology department at Aalborg university hospital between March 
and November 2003. Blood samples for cardiac troponin T (cTnT) were obtained 
on arrival, after 6-9 hours, and after 12-24 hours. cTnT fourth generation assay was 
used with a value of >0.03µg/L that satisfied the criteria of over 99
th
 percentile with 
coefficient of variation <10 %. The costs of cTnT analysis and hospital stay were 
calculated. The cost of cTnT sample analysis was 12 euro, and the cost of one day 
admission in the coronary care unit was estimated to be 1,550 euro. The effect of 
the third troponin results on patients' management plan was examined. 
Results: The median age of study patients was 62 years, male proportion was 62%, 
and one third of patients were known with angina pectoris (Table 2). Figure 9 
presents a flow chart of patients’ triage and observation period in the hospital. Out 
of the study population of 534 patients, 124 had at least one elevated cTnT level 
above the 99
th
 percentile. Of the 124 patients, there were only four (3.2 %) who had 
cTnT level increased solely in the third sample. There were 83 patients who 
continued their stay in the cardiology department after three normal cTnT samples 
due to different reasons. 58 out of these 83 patients continued their stay because 
they were referred to an early in-hospital coronary angiography; 35 patients on the 
basis of unstable angina pectoris and previous PCI or CABG, and 23 patients due to 
risk factors and/or ECG changes (Table 3). The medical history, clinical 
presentation, and ECG changes for the four patients with elevated third cTnT level 
presented in Table 4, which shows that they had the same characteristics as the 58 
patients mentioned above, which qualified them to be referred to in-hospital 
coronary angiography  regardless cTnT level. Hospital stay was extended for 275 
patients merely because of the third cTnT sample.  
Incremental cost of the third blood sample was estimated as (534 patients x Euro 12 
per cTnT analysis) + (275 patients x 0.5 day x Euro 1,550) = Euro 219,533. 
Approximately 1,400 patients with suspected NSTE-ACS are admitted to our 
department per year. Thus, total cost per year is: (1,400/534) x Euro 219,533 = Euro 
575,555.  
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Conclusion: The three-blood-sample strategy in the management of patients 
admitted for suspected NSTE-ACS did not contribute important information or 
change the patients’ management compared with using a two-blood-sample 
strategy. On the contrary, it resulted in an unnecessary extension of length of stay in 
the hospital and increased health care costs for these patients. 
 
Table 2: Baseline characteristics of patients admitted for suspected non-ST-
segment elevation acute coronary syndrome (n=534). 
Sex: male/female, %                                                                                      62:38 
Age years, median (range)                                                                          62 (27-96) 
Medical history before admission    
           Angina pectoris, n (%)                                                                       167 (31) 
           MI, n (%)                                                                                             48 (9) 
          CABG, n (%)                                                                                         22 (4) 
          Diabetes mellitus, n (%)                                                                        53 (10) 
Electrocardiogram, n (%) 
         Q-waves                                                                                                 41 (8) 
          Progressive ST-segment changes                                                          61 (12) 
          Non-progressive ST-segment changes                                                  71 (13) 
          Normal                                                                                                  284 (53) 
          Uncodable                                                                                             77 (14) 
MI = myocardial infarction; CABG = coronary artery by-pass graft 
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Figure 9: Flow chart over patients triage and management for patients admitted 
for non-ST-segment elevation acute coronary syndrome. NSTE-ACS = non-ST-
segment elevation acute coronary syndrome; CCU = coronary care unit. 
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Table 3: Causes of extension of hospital stay after three normal cardiac troponin T 
samples in patients with suspected non-ST-segment elevation acute coronary 
syndrome. 
Causes of extension of admission Number of 
patients 
CAG was performed due to unstable angina and previous 
PCI or CABG 
35 
CAG was performed based on risk factors, symptoms and/or 
ECG changes. 
23 
Pain management (known IHD with no possibility for 
revascularization) 
7 
Hospital stay extended to perform exercise test 12 
Other 6 
TOTAL 83 
CAG= coronary angiography; CABG = coronary artery by-pass graft; PCI = 
percutaneous coronary intervention; ECG = electrocardiogram; IHD = ischemic 
heart disease. 
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Table 4: Key information on the four patients with an elevated cardiac troponin T 
only in the third blood sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG = electrocardiogram; CABG = coronary artery by-pass graft; NIDDM = non-
insulin dependent diabetes mellitus; IHD: ischemic heart disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Medical History Symptoms ECG cTnT 1,2,3 
in µg/L 
1. Angina pectoris Severe chest pain Significant ST-segment 
depression > 0,5 mv 
0.02, 0.03, 
0.05 
2. Angina  pectoris 
Previous CABG  
Typical crescendo angina over 
1 month 
Normal 0.00, 0.03, 
0.06 
3. Angina  pectoris 
NIDDM                
Family history of IHD 
Heavy smoker 
Severe chest pain radiating to 
the left arm, disappeared after 
nitroglycerin 
Normal 0.00, 0.00, 
0.04 
4. Angina pectoris Severe continuous chest pain 
required nitroglycerin infusion 
Normal 0.00, 0.02, 
0.42 
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5. DISCUSSION 
Main Findings:  
The overall aim of this dissertation was to analyze aspects of Myocardial Infarction 
in terms of incidence, prognosis, and health care costs. 
The results of Study I confirmed that the overall incidence rate of first time MI 
declined from the year 1978 to 2012, and this decline was more prominent among 
males. The overall decline was mostly due to a fall in the incidence rates of the 
middle age groups, while both ends of the age scale showed a worrying increase in 
incidence rates of first MI among both genders. One-year case fatality declined 
significantly throughout the study period. 
The results of Study II showed that NSTEMI patients with non-obstructive 
coronary artery disease (both zero-vessel disease and diffuse atherosclerosis 
without significant stenosis) had risk of long-term adverse outcomes that is 
comparable to one-vessel and two-vessel disease patients, and that the 
atherosclerosis group had a worse prognosis compared with the zero-vessel disease 
group. Patients with zero-vessel disease had a risk of mortality and heart failure that 
is similar to the 2-vessel, and higher than the 1-vessel group (for mortality outcome 
if patients were non-diabetic). Patients with diffuse atherosclerosis had higher risk 
of mortality and heart failure, and similar risk of recurrent MI and stroke compared 
with the 1-vessel group. In addition, the atherosclerosis group had similar risk of 
mortality, heart failure, and stroke, but lower risk of recurrent MI compared with 
the 2-vessel group. The 3-vessel group had the worst prognosis of all groups. 
Lastly, the prognosis of the atherosclerosis group was worse than the zero-vessel 
disease group with higher mortality in diabetic patients, higher recurrent MI risk, 
and not significantly different heart failure and stroke risks. 
The results of Study III emphasized that the third measurement of cardiac troponin 
level in the blood for patients admitted for suspected acute coronary syndrome is 
not essential in the decision process regarding further investigations and 
management plan. Thus two-blood-sample strategy as opposed to the three-blood-
sample strategy can save about Euro 575,555 per year in the cardiology department 
at Aalborg University Hospital and that can be applied to all other hospitals, which 
can result in a huge reduction in health care costs for this patients' category.  
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5.1. Incidence rate of first myocardial infarction for all patients 
(Study I) 
This study confirmed a 37% decline in first MI comparing the year 1978 to 2012. 
These results support the findings of other studies from the USA,
67
 UK,
32
 and 
Sweden.
33
 In Denmark, a study by Schmidt and colleagues,
31
 examined incidence 
and prognosis of MI between 1984 and 2008 with special emphasis on prognostic 
impact of sex and co-morbidity. This study, however, did not clarify changes in MI 
incidence and mortality in different age groups for both genders. Our study in 
comparison to the above mentioned studies, included a larger cohort, a longer 
period of time and had particular focus on changing incidence and mortality rates in 
various age groups for both genders which was not examined in detail in any other 
study to the best of our knowledge.  
Our data truncated in 2012 showed that from 1978 to 1999 a consistent decline in 
incidence rates was observed, after which an increase by 23% comparing 2002 to 
1999, thereafter the incidence declined again. This was also observed in another 
study.
30 
The most likely explanation is the publication and endorsement of 
international criteria for the diagnosis of MI in Europe and the United States in 
2000. It was expected that there would be 26% more patients diagnosed with MI as 
compared with the previously used WHO criteria.
11
 This phenomenon was again 
observed, although with a limited effect, by an increase in the incidence rate of 
2.5% comparing 2006 with 2007 upon the endorsement of the 2007 version of the 
universal definition of myocardial infarction.
62
 
The explanation behind the decrease in incidence rate of first MI is only to be 
hypothesized upon, however it is not unrealistic to suggest that the decrease in some 
risk factors for MI might have contributed to incidence decline; cigarette smoking 
decreased in Denmark for men from 68% to 31% (54.4% decline) and for women 
from 47% to 25% (46.8% decline) comparing the year 1970 to 2006.
13
 Cholesterol 
levels and blood pressure decreased as well in Denmark's population since the 
1960s.
13
 These changes in risk factors were also observed in many other countries, 
for example in Sweden, smoking habit decreased in society by 55.4%, total 
cholesterol level decreased by 10.4%, and average systolic blood pressure 
decreased by 1.9% comparing the year 1986 with 2002.
68
 Many other studies in 
different countries confirmed the decrease in these risk factors for MI.
1,69–71 
On the 
other hand, other risk factors are increasing in society like diabetes mellitus and 
obesity.
13,68
 However, the significant decline in MI incidence suggests that the 
effect of the decreasing risk factors on incidence rate is greater than the effect of the 
increasing risk factors. 
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5.2. Gender-specific incidence rate of first myocardial infarction 
(Study I) 
Our results revealed that MI incidence rate was higher among men than women 
throughout the study period. This was also observed in another study from the 
UK.
32
 This observation confirms that male sex is a risk factor for ischemic heart 
disease. Moreover, other risk factors like blood pressure and cholesterol levels as 
well as smoking frequency are higher among men than women.
13,72,73
 Nevertheless, 
incidence decline was more significant among men than women comparing the 
study year 2012 to 1978. The explanation could partly be that men had a higher 
incidence rate at study start, and partly because the decline in other risk factors like 
smoking reduction was more obvious in men than in women since the early 1970s 
in Denmark.
13 
5.3. Incidence rate of first myocardial infarction for both 
genders divided into different age groups (Study I) 
Incidence decline was more prominent in age groups with a higher incidence rate at 
study start. The greatest decline was reported in men aged 70–79, followed by men 
aged 60–69, and then women aged 70–79 years. The most remarkable findings in 
this study were increasing incidence rate of first MI in younger age groups; women 
under the age of 50 years and men under the age of 40 years. Moreover, women 
aged 50–59 years, and men aged 40–49 years experienced an increase in incidence 
rate since 1996. In addition, the older age groups (men and women ≥90 years) 
experienced an increase in incidence throughout the study period. The reason 
behind these findings in younger age groups might be that the change in risk factors 
for MI was not evenly distributed throughout all age groups. According to another 
study, LDL-cholesterol levels declined from 2001 to 2008 in society among both 
genders and all age groups, however, this decline was lowest among younger age 
groups.
72
 Smoking rates declined as well from 1974 to 2012 among all age groups; 
nevertheless, the decline was less noticed among people less than 60 years of age. 
Furthermore, the percentage of smokers in society was higher in younger age 
groups.
14
 On the other hand, obesity and diabetes are increasing
15–17
 
 
especially 
among younger people,
18–20
 which could have a negative effect on incidence rates 
among younger age groups. 
Another reason for these findings might be immigration. We have a work in 
progress after this thesis (not published data) which shows that the proportion of 
non-Danish ethnicity from all patients with first MI increased from 2% in 1978 to 
12% in 2012 for patients under the age of 60, and from 2% to 6% for patients older 
than 60 years. 
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5.4. One-year mortality after first time myocardial infarction 
(Study I) 
One-year case fatality after admission for first MI decreased tremendously from 
1978 to 2012. Other studies have reported similar findings.
74–76
 Although there was 
an increase in incidence rates in early 2000s; this was, however, not accompanied 
by an increase in one-year case fatality or one-year heart failure complication to the 
same extent. The reason for this could be the use of cardiac troponin which could 
have led to the detection of minor injury to the myocardium. This was found in 
other studies as well.
67,77,78 
Nevertheless, the reduction in one-year mortality was colossal and cannot be solely 
explained by minor MI’s, but an important factor which could have played an 
important role is the use of evidence-based therapies (e.g. aspirin, beta blockers, 
lipid-lowering agents, and revascularization) leading to better management and 
prognosis. This was observed in other studies and registers.
79,80 
             
 
5.5. Mechanisms of myocardial injury in non-ST-segment 
elevation MI with non-obstructive coronary artery disease 
(Study II) 
Previous research led to the discovery of several possible mechanisms for 
myocardial injury in patients with NSTEMI without obstructive coronary arteries. 
Some of these mechanisms cause ischemia by for example a rupture in an 
athermanous plaque without the plaque causing significant stenosis and where clot 
has already dissolved before the angiography.
37
 Other studies which used 
provocation tests reported coronary artery spasm as a possible mechanism.
34,35,81,82
 
In addition, there were reports of microvascular disease,
36
 or thrombophilias 
whether congenital or acquired, as causes for NSTEMI with non-obstructive 
coronary artery disease.
34
 The abovementioned mechanisms are related to ischemia, 
however, a non-ischemic mechanism like myocarditis was also reported in 7% of 
patients diagnosed with NSTEMI when cardiac MRI was used,
9
 this is because 
myocarditis can resemble MI and fulfill the universal diagnostic criteria for MI.
12
 
Finely, other conditions can cause a demand-supply mismatch leading to type 2 MI, 
such as severe anemia, severe respiratory failure, tachy-brady arrhythmias or severe 
aortic valve disease.
12
 
5.6. Prevalence of NSTEMI with non-obstructive coronary artery 
disease (Study II) 
The proportion of NSTEMI with non-obstructive coronary arteries from all 
NSTEMI patients increased gradually to 18% in 2011 in our data. This can 
eventually be explained by the use of different generations and cutoffs of cardiac 
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troponin assay which became a high sensitive assay in the last years of the study.  
This development led to the detection of minor injury to the myocardium.
67,77,78
 
Other studies have reported a varied prevalence of MI with non-obstructive 
coronary arteries from 4-13%, depending on the type of acute coronary syndrome 
used (STEMI, NSTEMI, and/or unstable angina).
8–10,83
  
5.7. Characteristics of patients with NSTEMI and non-
obstructive coronary artery disease (Study II) 
There were significantly more females in both the 0-vessel and the atherosclerosis 
groups than all other groups. This finding confirms other studies,
8,38–40,43,83,84
 
however, some of these studies reported that NSTEMI patients with non-obstructive 
coronary artery disease are generally younger and have less risk factors for 
ischemic heart disease than patients with obstructive coronary artery disease. These 
studies, nevertheless, did not divide patients with non-obstructive or obstructive 
coronary artery disease into subgroups. Our study illustrates that patients have 
different characteristics within both non-obstructive and obstructive coronary artery 
disease large groups. Thus in our study patients with 0-vesel disease were younger, 
more likely to be females and have less risk profile than those with diffuse 
atherosclerosis. This was also observed in another study.
40
 Moreover, patients in the 
0-vessel group had generally a comparable profile to the1-vessel group and those in 
the atherosclerosis group were comparable to the 2-vessel group. The 3-vessel 
group had higher risk profile than all other groups, which might have contributed to 
the generally higher risk profile in obstructive coronary artery disease group 
compared with non-obstructive group in studies which compared these broad 
groups. 
5.8. Long-term mortality for patients with NSTEMI according to 
their coronary pathology (Study II) 
Our study illustrated that mortality risk was higher in patients with 0-vessel disease 
(if they were non-diabetic) and diffuse atherosclerosis compared with patients with 
1-vessel disease, and not significantly different than patients with 2-vessel disease. 
Another study reported that NSTEMI patients with normal coronaries had no 
difference in mortality than both atherosclerosis, 1-vessel, and 2-vessel disease not 
involving proximal LAD,
44
 while other studies which compared obstructive versus 
non-obstructive coronary arteries in NSTEMI patients without sub-differentiation of 
these two groups demonstrated that mortality risk was similar in these broad 
groups.
39,40,43,84
 Moreover, mortality risk of type 2 MI was reported before to be 
comparable to type 1 MI,
85,86
 and our study did not distinguish between type 1 and 
type 2 MI, if the latter was coded as NSTEMI as the primary diagnosis in the 
register.  
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The reason for our findings can only be speculated upon, but it is not unreasonable 
to assume that patients in the 0-vessel group are different from those in the 
atherosclerosis group. The 0-vessel group is most likely to be very heterogeneous 
and includes a variety of underlying conditions which may not have been 
investigated in detail during the admission.  Some of these conditions could cause 
fatality and morbidity without directly involving coronary artery disease, while the 
atherosclerosis group patients could have the same underlying ischemic heart 
disease as NSTEMI patients with obstructive coronary arteries, but these patients 
are less likely to receive evidence-based medical treatment after MI and more likely 
to discontinue platelet inhibition treatment if this was started.
39,43
 
5.10. Long-term risk of recurrent MI after first NSTEMI (Study II) 
The risk of recurrent MI was similar between patients with diffuse atherosclerosis 
and patients with 1-vessel disease, and both groups had a higher risk than patients 
with 0-vessel disease. 
A possible explanation can be that atherosclerotic plaque burden could be similar 
among atherosclerosis and 1-vessel patients, but higher than 0-vessel patients. 
Yamagishi and collogues examined 106 patients with no stenosis >50% but 
atherosclerosis with intra vascular ultrasound system and reported within a mean 
follow up period of 21 months, that 11.3%  were admitted for acute coronary 
syndrome with culprit lesion in the previously examined plaque, and 3.7% with 
culprit lesion in a previously normal coronary artery.
87
 Maehara and collogues 
reported that with the use of intra vascular ultrasound system, 11.6% of ruptured 
plaques were not detected by angiography.
88
 Moreover, acute coronary syndrome 
with high grade stenosis (>75%) can occur in about 50% of lesions, which 
previously found not significant, and treated medically.
89
 On a 3 years follow-up, 
12.9% of major adverse cardiovascular events were related to culprit lesion and 
11.6% were related to non-culprit lesion, most of non-culprit lesions were 
angiographically mild lesions at base-line.
90
  
Other studies have shown that patients with non-obstructive coronary artery disease 
have lower risk of MI than obstructive coronary artery disease,
39,40
 however, these 
studies did not perform sub classification of obstructive coronary artery disease 
patients.  
5.9. Long-term heart failure complication after first NSTEMI 
(Study II) 
Our results demonstrated that heart failure risk was higher among patients in the 
with 0-vessel or atherosclerosis groups than those in the 1-vessel, and similar to 
those in the 2-vessel group. There was a study that reported the risk of heart failure 
to be the same among patients with acute coronary syndrome with or without 
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obstructive coronary artery disease.
84
 This study was, however, among patients ≥ 75 
years, and did not differentiate between subgroups of obstructive or non-obstructive 
coronary artery disease. 
One explanation of these findings could be that, although we excluded patients 
known with heart failure from our study, some of the patients in the normal 0-vessel 
or atherosclerosis group of the study could have been admitted with acute heart 
failure with signs, symptoms, and cardiac markers that resembled MI. Therefore 
they received the diagnosis NSTEMI upon discharge. It is well known that acute 
heart failure can cause myocardial injury resembling myocardial infarction.
12
 Other 
patients could have also suffered from some type of non-ischemic cardiomyopathy 
or hypertensive heart disease which became manifest at a later stage. 
5.11. Long-term stroke risk after first NSTEMI according to 
coronary pathology (Study II) 
There was no significant difference in stroke risk among NSTEMI patients across 
coronary pathology subgroups. This finding supports other studies,
39,43
 however, 
these studies did not differentiate between different subtypes of obstructive 
coronary artery disease. 
5.12. Overall explanation for outcomes differences between 
NSTEMI patients accroding to coronary artery pathology on the 
angiography (Study II) 
An overall explanation for the differences in outcomes maybe hypothesized as 0-
vessel disease patients might have a non-ischemic basis for their MI, such as acute 
heart failure, myocarditis, arrhythmias, or other causes which predispose them to 
higher future heart failure and higher or comparable mortality compared with 1-
vessel patients. While diffuse atherosclerosis patients have an extended 
atherosclerotic disease without focal significant stenosis, nevertheless, they are less 
likely to receive the recommended medical therapy,
39,43
 therefore their prognosis is 
worse than 1-vessel and comparable to 2-vessel patients. 
5.13. Cost-effectiveness of the third blood sample of cardiac 
troponin (Study III) 
Although the value of cardiac troponin I and T for risk stratification in non–ST-
segment elevation acute coronary syndrome is well established,
91–97
 and their use in 
patients with suspected acute coronary syndrome is cost-effective, 
98–100
 the cost 
effectiveness of the routine withdrawing of three or more blood samples of troponin 
has not been examined. The strategy of serial measurement of troponin has been 
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used over a long time to increase safety for the patients in ruling out MI 
diagnosis.
48,49
 
This study affirmed that the third measurement of cardiac troponin is not cost 
effective because it costs our department Euro 575,555 per year without adding 
important information regarding the management of patients. Thus, it is safe to 
reevaluate patients after the second blood sample of troponin and make a decision 
on further management or discharge. Other studies have also reported the safety of 
discharge from the hospital after a few hours of observation and negative troponin 
levels.
101,102
 On applying the European Society of Cardiology guidelines on the 
management of non-ST-elevation acute coronary syndrome,
52
 the four patients with 
normal first two troponin levels in our study, would all have been referred to early 
coronary angiography due to either ST-segment changes in the ECG (patient 1), 
previous CABG with typical crescendo angina over 1 month (patient 2), diabetes 
mellitus with high risk profile (patient 3); or to an urgent invasive strategy due to 
refractory angina (patient 4). Moreover our data showed 58 patients who were 
referred to an early (in hospital) coronary angiography based on a risk profile 
and/or ECG changes. This would have been applied for the four patients with 
elevated third sample of cTnT even before the results of this sample became 
available.  
Besides reducing expenses, the prospective of withdrawing two troponin blood 
samples instead of three will lead to earlier re-evaluation of patients as soon as the 
second troponin results becomes available without delay. 
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6. STRENGTHS AND LIMITATIONS 
The strengths of our study include the large number of unselected patient 
populations including men and women, different age groups, and patients of both 
Danish origin as well as immigrants; this helps generalize our findings.  
However, our studies do have some limitations. In Study I different thresholds for 
cardiac biomarkers throughout study years might have affected the incidence rates, 
and some patients who were considered as having first MI during the early years of 
the study might have suffered a MI prior to the introduction of national registers. 
That is why we did a sensitivity analysis using all MIs. 
In both Study I and II we had no access to clinical data as symptoms, signs, ECG 
changes, and results of blood tests. Moreover, like all other register-based studies, 
the validity of these studies depends much on the validity of MI diagnosis in the 
Danish National Patient Register, which was estimated to be 92-93%.  
In Study II, patients with MI type 2 might have been included if the primary 
discharge diagnosis was NSTEMI. Moreover, a core-lab for coronary angiography 
assessment was not used, thus inter-operator variation might exist. Only patients 
who underwent coronary angiography were included which might make 
generalizations of the results limited. Finally there was no adjudication committee 
to verify clinical events. In angiography database the definitions of 0-vessel disease 
and diffuse atherosclerosis were subject for inter- and intra-hospital different 
interpretations, thus some of the patients with diffuse atherosclerosis might have 
been coded as 0-vessel disease. However, this misclassification would lead to 
minimize the differences between 0-vessel and atherosclerosis groups, thus the real 
differences between these groups in outcome may be larger than that reported in our 
article. 
In Study III, a limitation of this study might be that the study was conducted using 
4
th
 generation cTnT, while many institutions nowadays are using high sensitive 
cTnT. However, the use of high sensitive cTnT with its even lower threshold leads 
to the detection of troponin in the blood with less time from symptoms start than 4
th
 
generation cTnT, thus the observation period for suspected coronary artery 
syndrome might become even shorter with these high sensitive assays. 
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7. CONCLUSION 
Myocardial infarction is decreasing in incidence and patients' prognosis is improving 
but there are still challenges in specific age groups and subgroups of myocardial 
infarction with non-obstructive coronary artery disease. 
More detailed conclusions are based on our studies: 
Study I: The results of this nation-wide population-based 35-year study with 
316,790 patients demonstrate that the incidence rates of first myocardial infarction 
has generally decreased through the study period until 2012 in the majority of age 
groups for both genders, nevertheless, younger age groups (women less than 60 
years and men less than 50 years of age) have experienced an increase in incidence 
rates at least since 1996. Moreover, incidence rates increased in the oldest age group 
(men and women 90 years and older) throughout the study period. These findings 
require further investigation to confirm age-specific incidence changes which might 
lead to focus more preventive measurements to target the affected age groups. Study 
results emphasize the remarkable decline in one-year case fatality after admission 
for first MI in all age groups of either gender. 
Study II: Non-ST-segment elevation myocardial infarction patients with a non-
obstructive coronary artery disease on coronary angiography, both normal 
coronaries and atherosclerosis with stenosis <50%, have a non negligible risk of 
adverse long term outcomes. Patients with zero-vessel disease have a higher risk of 
mortality than the one-vessel disease group if they were non-diabetics, and similar 
risk if they were diabetics. They have, in addition, a higher risk of heart failure than 
one-vessel disease, and similar risk of stroke to all subgroups of obstructive 
coronary artery disease. 
Patients with diffuse atherosclerosis have a higher risk of mortality and heart failure 
than one-vessel disease, similar to two-vessel disease and three-vessel disease 
groups. Moreover, they are similar to all other groups in terms of stroke risk, and 
have a similar risk of recurrent MI to one-vessel disease. 
Finally, patients with zero-vessel disease have better prognosis than those with 
diffuse atherosclerosis with less recurrent MI and mortality (for mortality if patients 
were diabetic), but similar risk of heart failure and stroke. 
Thus these two NSTEMI groups with non-obstructive coronary arteries should 
probably be considered separately in future research and further investigation is 
needed to illuminate both the mechanism of myocardial injury and the optimal 
management and follow-up plan for each of these two subgroups of patients. 
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Study III: This study confirms that the third cardiac troponin T blood sample is not 
cost-effective as it does not add further important information to be used in patients' 
management and investigations plan. On the contrary, it leads to an unnecessary 
extended length of stay in the hospital which leads to increased health care costs. 
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8. CLINICAL IMPLICATIONS AND 
FUTURE RESEARCH 
As a consequence of Study III, our department dropped the routine use of the third 
blood sample of troponin, and encouraged the practice of re-evaluation as soon as 
the result of the second sample is available. 
Future research: 
1- Focus studies on age groups were we found increasing MI incidence rates, 
especially men less than 50 years, and women less than 60 years of age for 
better understanding of this phenomenon and focus preventive measures. 
 
2- Developing an algorithm to try to predict which patients admitted with 
acute NSTEMI might have non-obstructive coronary artery disease, and 
might be referred to a non-invasive modality to investigate their 
atherosclerotic burden. 
 
3- Investigate medical treatment differences between NSTEMI patients with 
and without obstructive coronary artery disease in different subgroups. 
 
4- Design a study with extensive investigation program to find out the cause 
for myocardial injury in MI patients with non-obstructive coronary artery 
disease. 
 
 
 
 
 
 
 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
70
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
71 
REFERENCES 
1.  National Institutes for Health, National Heart, Lung  and BI. Morbidity and 
Mortality: 2007 Chartbook on Cardiovascular, Lung, and Blood Disease 
[Internet]. p. http://www.nhlbi.nih.gov/resources/docs/07 – chtbk.p. 
Available from: http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf. 
2.  WHO. World Health Organization fact sheet No.310. 2014 [Internet]. 2014 
[cited 2015 May 30]. Available from: 
http://www.who.int/mediacentre/factsheets/fs310/en/ 
3.  Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, 
Scarborough P RM. European Cardiovascular Disease Statistics [Internet]. 
Eur. Hear. Network, Brussels, Eur. Soc. Cardiol. Sophia Antip. 2012 [cited 
2015 May 30]. p. http://ehnheart.org/cvd – statistics.2012. Available from: 
http://www.ehnheart.org/cvd-statistics.html 
4.  Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, 
Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, 
Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, 
Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, 
Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, et al. 
Heart disease and stroke statistics--2013 update: a report from the American 
Heart Association. Circulation. 2013;127:e6–e245.  
5.  Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in 
sudden cardiac ischemic death. N Engl J Med. 1984;310:1137–1140.  
6.  Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R. 
Coronary plaque erosion without rupture into a lipid core. A frequent cause 
of coronary thrombosis in sudden coronary death. Circulation. 
1996;93:1354–1363.  
7.  Wang L, Parodi G, Maehara A, Valenti R, Migliorini A, Vergara R, 
Carrabba N, Mintz GS, Antoniucci D. Variable underlying morphology of 
culprit plaques associated with ST-elevation myocardial infarction: an 
optical coherence tomography analysis from the SMART trial. Eur Heart J 
Cardiovasc Imaging. 2015;jev105 – .  
8.  Agewall S, Daniel M, Eurenius L, Ekenbäck C, Skeppholm M, Malmqvist 
K, Hofman-Bang C, Collste O, Frick M, Henareh L, Jernberg T, Tornvall P. 
Risk factors for myocardial infarction with normal coronary arteries and 
myocarditis compared with myocardial infarction with coronary artery 
stenosis. Angiology. 2012;63:500–503.  
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
72
 
9.  Collste O, Sörensson P, Frick M, Agewall S, Daniel M, Henareh L, 
Ekenbäck C, Eurenius L, Guiron C, Jernberg T, Hofman-Bang C, Malmqvist 
K, Nagy E, Arheden H, Tornvall P. Myocardial infarction with normal 
coronary arteries is common and associated with normal findings on 
cardiovascular magnetic resonance imaging: results from the Stockholm 
Myocardial Infarction with Normal Coronaries study. J Intern Med. 
2013;273:189–196.  
10.  Stensaeth KH, Fossum E, Hoffmann P, Mangschau A, Klow NE. Clinical 
characteristics and role of early cardiac magnetic resonance imaging in 
patients with suspected ST-elevation myocardial infarction and normal 
coronary arteries. Int J Cardiovasc Imaging. 2011;27:355–365.  
11.  Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction 
redefined--a consensus document of The Joint European Society of 
Cardiology/American College of Cardiology Committee for the redefinition 
of myocardial infarction. J Am Coll Cardiol. 2000;36:959–969.  
12.  Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, 
Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen 
PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, 
Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky 
BF, Steg PG, Wijns W, Bassand J-P, Menasché P, Ravkilde J, et al. Third 
universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–
2567.  
13.  The Danish National Institue of Public Health. The Public Health Report 
Denmark 2007 [Internet]. Natl. Instiute Public Heal. 2007 [cited 2015 Apr 
12]. Available from: http://www.si-folkesundhed.dk/upload/fsr.07.eng.pdf 
14.  UK Office for National Statistics. Opinions and Lifestyle Survey, Smoking 
Habits Amongst Adults, 2012 [Internet]. UK Off. Natl. Stat. 2013 [cited 
2015 Apr 12]. Available from: Availabe at 
http://www.ons.gov.uk/ons/dcp171776_328041.pdf 
15.  Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, 
Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh 
NME, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, 
Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, 
Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang J-C, et al. 
Global, regional, and national prevalence of overweight and obesity in 
children and adults during 1980–2013: a systematic analysis for the Global 
Burden of Disease Study 2013. Lancet. 2014;  
REFERENCES 
73 
16.  Li M-Z, Su L, Liang B-Y, Tan J-J, Chen Q, Long J-X, Xie J-J, Wu G-L, 
Yan Y, Guo X-J, Gu L. Trends in prevalence, awareness, treatment, and 
control of diabetes mellitus in mainland china from 1979 to 2012. Int J 
Endocrinol. 2013;2013:753150.  
17.  Promotion NC for CDP and H. Diabetes Report Card 2012 [Internet]. 
Diabetes Rep. Card. 2012. Available from: 
http://www.cdc.gov/diabetes/pubs/pdf/diabetesreportcard.pdf 
18.  Holden SH, Barnett AH, Peters JR, Jenkins-Jones S, Poole CD, Morgan CL, 
Currie CJ. The incidence of type 2 diabetes in the United Kingdom from 
1991 to 2010. Diabetes Obes Metab. 2013;15:844–852.  
19.  Liese AD, D’Agostino RB, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, 
Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE. 
The burden of diabetes mellitus among US youth: prevalence estimates from 
the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118:1510–
1518.  
20.  Sharp PS, Brown B, Qureshi A. Age at diagnosis of diabetes in a secondary 
care population: 1992--2005. Br J Diabetes Vasc Dis. 2008;8:92–95.  
21.  Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg 
L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and 
in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 
1998;339:861–867.  
22.  Elveback LR, Connolly DC, Melton LJ. Coronary heart disease in residents 
of Rochester, Minnesota. VII. Incidence, 1950 through 1982. Mayo Clin 
Proc. 1986;61:896–900.  
23.  Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Recent changes in attack and 
survival rates of acute myocardial infarction (1975 through 1981). The 
Worcester Heart Attack Study. JAMA. 1986;255:2774–2779.  
24.  Rosamond WD, Folsom AR, Chambless LE, Wang CH. Coronary heart 
disease trends in four United States communities. The Atherosclerosis Risk 
in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001;30 Suppl 
1:S17–S22.  
25.  Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975 to 
1995) long experience in the incidence, in-hospital and long-term case-
fatality rates of acute myocardial infarction: a community-wide perspective. 
J Am Coll Cardiol. 1999;33:1533–1539.  
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
74
 
26.  McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn 
H, Luepker R V. Recent trends in acute coronary heart disease--mortality, 
morbidity, medical care, and risk factors. The Minnesota Heart Survey 
Investigators. N Engl J Med. 1996;334:884–890.  
27.  McGovern PG, Jacobs DR, Shahar E, Arnett DK, Folsom AR, Blackburn H, 
Luepker R V. Trends in acute coronary heart disease mortality, morbidity, 
and medical care from 1985 through 1997: the Minnesota heart survey. 
Circulation. 2001;104:19–24.  
28.  Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk factors and the 
decline in mortality from cardiovascular disease. The Framingham Heart 
Study. N Engl J Med. 1990;322:1635–1641.  
29.  Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular 
disease mortality, incidence, and case fatality rates in adults in the United 
States. Am J Med. 2004;117:219–227.  
30.  Floyd KC, Yarzebski J, Spencer FA, Lessard D, Dalen JE, Alpert JS, Gore 
JM, Goldberg RJ. A 30-year perspective (1975-2005) into the changing 
landscape of patients hospitalized with initial acute myocardial infarction: 
Worcester Heart Attack Study. Circ Cardiovasc Qual Outcomes. 2009;2:88–
95.  
31.  Schmidt M, Jacobsen JB, Lash TL, Bøtker HE, Sørensen HT. 25 year trends 
in first time hospitalisation for acute myocardial infarction, subsequent short 
and long term mortality, and the prognostic impact of sex and comorbidity: a 
Danish nationwide cohort study. BMJ. 2012;344:e356.  
32.  Davies AR, Grundy E, Nitsch D, Smeeth L. Constituent country inequalities 
in myocardial infarction incidence and case fatality in men and women in 
the United Kingdom, 1996-2005. J Public Health (Oxf). 2011;33:131–138.  
33.  Yang D, Dzayee DAM, Beiki O, Faire U de, Alfredsson L, Moradi T. 
Incidence and case fatality after day 28 of first time myocardial infarction in 
Sweden 1987-2008. Eur J Prev Cardiol. 2012;19:1304–1315.  
34.  Costa A Da, Isaaz K, Faure E, Mourot S, Cerisier A, Lamaud M. Clinical 
characteristics, aetiological factors and long-term prognosis of myocardial 
infarction with an absolutely normal coronary angiogram; a 3-year follow-
up study of 91 patients. Eur Heart J. 2001;22:1459–1465.  
35.  Wang C-H, Kuo L-T, Hung M-J, Cherng W-J. Coronary vasospasm as a 
possible cause of elevated cardiac troponin I in patients with acute coronary 
REFERENCES 
75 
syndrome and insignificant coronary artery disease. Am Heart J. 
2002;144:275–281.  
36.  Yetkin E, Turhan H, Erbay AR, Aksoy Y, Senen K. Increased thrombolysis 
in myocardial infarction frame count in patients with myocardial infarction 
and normal coronary arteriogram: a possible link between slow coronary 
flow and myocardial infarction. Atherosclerosis. 2005;181:193–199.  
37.  Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GBJ, Feit F, Pena-
Sing I, Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach I 
V, Hochman JS. Mechanisms of myocardial infarction in women without 
angiographically obstructive coronary artery disease. Circulation. 
LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, 
PHILADELPHIA, PA 19106-3621 USA; 2011;124:1414–1425.  
38.  Patel MR, Chen AY, Peterson ED, Newby LK, Pollack C V, Brindis RG, 
Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, 
Harrington RA, Roe MT. Prevalence, predictors, and outcomes of patients 
with non-ST-segment elevation myocardial infarction and insignificant 
coronary artery disease: results from the Can Rapid risk stratification of 
Unstable angina patients Suppress ADverse outcomes with Early. Am Heart 
J. 2006;152:641–647.  
39.  Rossini R, Musumeci G, Lettieri C. Long-term prognosis of patients with 
acute coronary syndrome and non-obstructive coronary artery disease. J Am 
…. 2011;  
40.  Ohlow M-A, Wong V, Brunelli M, Korn H von, Farah A, Memisevic N, 
Richter S, Tukhiashvili K, Lauer B. Acute coronary syndrome without 
critical epicardial coronary disease: prevalence, characteristics, and 
outcome. Am J Emerg Med. 2015;33:150–154.  
41.  Planer D, Mehran R, Ohman EM, White HD, Newman JD, Xu K, Stone 
GW. Prognosis of patients with non-ST-segment-elevation myocardial 
infarction and nonobstructive coronary artery disease: propensity-matched 
analysis from the acute catheterization and urgent intervention triage 
strategy trial. Circ Cardiovasc Interv. 2014;7:285–293.  
42.  Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, 
Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, 
Storey RF, Wijns W, Zahger D. ESC Guidelines for the management of 
acute coronary syndromes in patients presenting without persistent ST-
segment elevation: The Task Force for the management of acute coronary 
syndromes (ACS) in patients presenting without persistent ST-segment 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
76
 
elevatio. Eur Heart J. 2011;32:2999–3054.  
43.  Andre R, André RE. Prevalence, clinical profile and 3-year survival of acute 
myocardial infarction patients with and without obstructive coronary 
lesions: The FAST-MI 2005 registry. Int J Cardiol. 2014;172.  
44.  Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson 
ML. Characteristics and outcomes of patients with acute myocardial 
infarction and angiographically normal coronary arteries. Am J Cardiol. 
2005;95:261–263.  
45.  Bugiardini R, Manfrini O, Ferrari GM De. Unanswered questions for 
management of acute coronary syndrome: risk stratification of patients with 
minimal disease or normal findings on coronary angiography. Arch Intern 
Med. 2006;166:1391–1395.  
46.  Sugiyama T, Hasegawa K, Kobayashi Y, Takahashi O, Fukui T, Tsugawa Y. 
Differential Time Trends of Outcomes and Costs of Care for Acute 
Myocardial Infarction Hospitalizations by ST Elevation and Type of 
Intervention in the United States, 2001-2011. J Am Heart Assoc. 2015;4.  
47.  Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Khalaf M Al, 
Collinson P, Morris F, Evans P, Wang J. Systematic review, meta-analysis 
and economic modelling of diagnostic strategies for suspected acute 
coronary syndrome. Health Technol Assess. 2013;17:v – vi, 1–188.  
48.  Thygesen K, Ravkilde J. Triage of chest pain patients based on early risk 
stratification using sensitive cardiac markers. Eur Heart J. 2000;21:347–
348.  
49.  Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, 
Lee KL, Hamm CW, Katus HA, Cianciolo C, Granger CB, Topol EJ, Califf 
RM. Value of serial troponin T measures for early and late risk stratification 
in patients with acute coronary syndromes. The GUSTO-IIa Investigators. 
Circulation. 1998;98:1853–1859.  
50.  Hjortshøj S, Dethlefsen C, Kristensen SR, Ravkilde J. Improved assay of 
cardiac troponin I is more sensitive than other assays of necrosis markers. 
Scand J Clin Lab Invest. 2008;68:130–133.  
51.  Szymański FM, Grabowski M, Filipiak KJ, Karpiński G, Hrynkiewicz A, 
Stolarz P, Oreziak A, Rudowski R, Opolski G. Prognostic implications of 
myocardial necrosis triad markers’ concentration measured at admission in 
patients with suspected acute coronary syndrome. Am J Emerg Med. 
REFERENCES 
77 
2007;25:65–68.  
52.  Bassand J-P, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-
Avilés F, Fox KAA, Hasdai D, Ohman EM, Wallentin L, Wijns W. 
Guidelines for the diagnosis and treatment of non-ST-segment elevation 
acute coronary syndromes. Eur Heart J. 2007;28:1598–1660.  
53.  Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 
2011;39:22–25.  
54.  Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The 
Danish National Hospital Register. A valuable source of data for modern 
health sciences. Dan Med Bull. 1999;46:263–268.  
55.  Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. 
Scand J Public Health. 2011;39:30–33.  
56.  Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription 
Registry. Scand J Public Health. 2011;39:38–41.  
57.  Denmark S. Denmrak’s Population statistics [Internet]. 2015. p. 
http://www.statistikbanken.dk/statbank5a/SelectVar. Available from: 
http://www.statistikbanken.dk/statbank5a/SelectVarVal/Define.asp?Maintab
le=FOLK1&PLanguage=1 
58.  Schmidt M, Maeng M, Jakobsen C-J, Madsen M, Thuesen L, Nielsen PH, 
Bøtker HE, Sørensen HT. Existing data sources for clinical epidemiology: 
The Western Denmark Heart Registry. Clin Epidemiol. 2010;2:137–144.  
59.  Panteghini M, Pagani F, Yeo K-TJ, Apple FS, Christenson RH, Dati F, Mair 
J, Ravkilde J, Wu AHB. Evaluation of imprecision for cardiac troponin 
assays at low-range concentrations. Clin Chem. 2004;50:327–332.  
60.  Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The 
validity of the diagnosis of acute myocardial infarction in routine statistics: a 
comparison of mortality and hospital discharge data with the Danish 
MONICA registry. J Clin Epidemiol. 2003;56:124–130.  
61.  Joensen AM, Jensen MK, Overvad K, Dethlefsen C, Schmidt E, Rasmussen 
L, Tjønneland A, Johnsen S. Predictive values of acute coronary syndrome 
discharge diagnoses differed in the Danish National Patient Registry. J Clin 
Epidemiol. 2009;62:188–194.  
62.  Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
78
 
HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, 
Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Wall EE Van 
der, Bassand J-P, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams 
DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, et al. 
Universal definition of myocardial infarction. Circulation. 2007. p. 2634–
2653.  
63.  Kümler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Køber L, Torp-
Pedersen C. Accuracy of a heart failure diagnosis in administrative registers. 
Eur J Heart Fail. 2008;10:658–660.  
64.  Flu W-J, Kuijk J-P van, Galal W, Kuiper R, Ven LL van de, Verhagen HJM, 
Bax JJ, Poldermans D. Prevalence and pharmacological treatment of left-
ventricular dysfunction in patients undergoing vascular surgery. Eur J Heart 
Fail. 2010;12:288–293.  
65.  McMurray JJ V, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska 
A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved 
ejection fraction: clinical characteristics of 4133 patients enrolled in the I-
PRESERVE trial. Eur J Heart Fail. 2008;10:149–156.  
66.  Andersson C, Norgaard ML, Hansen PR, Fosbøl EL, Schmiegelow M, 
Weeke P, Olesen JB, Raunsø J, Jørgensen CH, Vaag A, Køber L, Torp-
Pedersen C, Gislason GH. Heart failure severity, as determined by loop 
diuretic dosages, predicts the risk of developing diabetes after myocardial 
infarction: a nationwide cohort study. Eur J Heart Fail. 2010;12:1333–1338.  
67.  Yeh RW, Sidney S, Chandra M, Sorel M, Selby J V, Go AS. Population 
trends in the incidence and outcomes of acute myocardial infarction. N Engl 
J Med. 2010;362:2155–2165.  
68.  Björck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the 
decreasing coronary heart disease mortality in Sweden between 1986 and 
2002. Eur Heart J. 2009;30:1046–1056.  
69.  Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O’Hagan P, 
Montalescot G, Ballantyne CM, Cannon CP. Nine-year trends in 
achievement of risk factor goals in the US and European outpatients with 
cardiovascular disease. Am Heart J. 2008;156:719–727.  
70.  Arnett DK, McGovern PG, Jacobs DR, Shahar E, Duval S, Blackburn H, 
Luepker R V. Fifteen-year trends in cardiovascular risk factors (1980-1982 
through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol. 
2002;156:929–935.  
REFERENCES 
79 
71.  Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in 
hypertension prevalence, awareness, treatment, and control rates in United 
States adults between 1988-1994 and 1999-2004. Hypertension. 
2008;52:818–827.  
72.  Kaufman HW, Blatt AJ, Huang X, Odeh MA, Superko HR. Blood 
cholesterol trends 2001-2011 in the United States: analysis of 105 million 
patient records. PLoS One. 2013;8:e63416.  
73.  Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control 
of hypertension in North America, North Africa and Asia. J Hum Hypertens. 
2004;18:545–551.  
74.  Briffa T, Hickling S, Knuiman M, Hobbs M, Hung J, Sanfilippo FM, 
Jamrozik K, Thompson PL. Long term survival after evidence based 
treatment of acute myocardial infarction and revascularisation: follow-up of 
population based Perth MONICA cohort, 1984-2005. BMJ. 2009;338:b36.  
75.  D’Ascenzo F, Gonella A, Quadri G, Longo G, Biondi-Zoccai G, Moretti C, 
Omedè P, Sciuto F, Gaita F, Sheiban I. Comparison of mortality rates in 
women versus men presenting with ST-segment elevation myocardial 
infarction. Am J Cardiol. 2011;107:651–654.  
76.  Kostis WJ, Deng Y, Pantazopoulos JS, Moreyra AE, Kostis JB. Trends in 
mortality of acute myocardial infarction after discharge from the hospital. 
Circ Cardiovasc Qual Outcomes. 2010;3:581–589.  
77.  Parikh NI, Gona P, Larson MG, Fox CS, Benjamin EJ, Murabito JM, 
O’Donnell CJ, Vasan RS, Levy D. Long-term trends in myocardial 
infarction incidence and case fatality in the National Heart, Lung, and Blood 
Institute’s Framingham Heart study. Circulation. 2009;119:1203–1210.  
78.  Myerson M, Coady S, Taylor H, Rosamond WD, Goff DC. Declining 
severity of myocardial infarction from 1987 to 2002: the Atherosclerosis 
Risk in Communities (ARIC) Study. Circulation. 2009;119:503–514.  
79.  Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz 
DA, Frederick PD, Every N. Temporal trends in the treatment of over 1.5 
million patients with myocardial infarction in the US from 1990 through 
1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll 
Cardiol. 2000;36:2056–2063.  
80.  Heidenreich PA, McClellan M. Trends in treatment and outcomes for acute 
myocardial infarction: 1975-1995. Am J Med. 2001;110:165–174.  
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
80
 
81.  Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. 
Coronary artery spasm as a frequent cause of acute coronary syndrome: The 
CASPAR (Coronary Artery Spasm in Patients With Acute Coronary 
Syndrome) Study. J Am Coll Cardiol. 2008;52:523–527.  
82.  Rocca DG Della, Pepine CJ. What causes myocardial infarction in women 
without obstructive coronary artery disease? Circulation. 2011;124:1404–
1406.  
83.  Cortell A, Sanchis J, Bodí V, Núñez J, Mainar L, Pellicer M, Miñana G, 
Santas E, Domínguez E, Palau P, Llácer A. Non-ST-elevation acute 
myocardial infarction with normal coronary arteries: predictors and 
prognosis. Rev española Cardiol. 2009;62:1260–1266.  
84.  Wong V, Farah A, Korn H von, Memisevic N, Richter S, Tukhiashvili K, 
Lauer B, Ohlow M-A. Patients ≥ 75 years with acute coronary syndrome but 
without critical epicardial coronary disease: prevalence, characteristics, and 
outcome. J Geriatr Cardiol. 2015;12:11–16.  
85.  Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 
myocardial infarction: should we be paying more attention? J Am Coll 
Cardiol. ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW 
YORK, NY 10010-1710 USA; 2014;63:2079–2087.  
86.  Nelson SE, Sandoval Y, Smith SW, Schulz KM, Murakami M, Pearce LA, 
Apple F. ROLE OF DELTA CARDIAC TROPONIN I TO DISTINGUISH 
BETWEEN TYPE I NSTEMI AND TYPE II MYOCARDIAL 
INFARCTION. J Am Coll Cardiol. 2013;61:E234.  
87.  Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S, 
Ito K, Yasumura Y, Miyatake K. Morphology of vulnerable coronary 
plaque: insights from follow-up of patients examined by intravascular 
ultrasound before an acute coronary syndrome. J Am Coll Cardiol. 
2000;35:106–111.  
88.  Maehara A, Mintz GS, Bui AB, Walter OR, Castagna MT, Canos D, Pichard 
AD, Satler LF, Waksman R, Suddath WO, Laird JR, Kent KM, Weissman 
NJ. Morphologic and angiographic features of coronary plaque rupture 
detected by intravascular ultrasound. J Am Coll Cardiol. 2002;40:904–910.  
89.  Saito T, Date H, Taniguchi I, Nakamura S, Oka H, Mizuno Y, Noda K, 
Yamashita S, Oshima S, Yasue H. Angiographic evaluation of culprit 
lesions in acute coronary syndrome: relation to the original site on previous 
coronary angiography. Jpn Circ J. 1998;62:359–363.  
REFERENCES 
81 
90.  Stone GW, Maehara A, Lansky AJ, Bruyne B de, Cristea E, Mintz GS, 
Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White 
R, Zhang Z, Serruys PW. A prospective natural-history study of coronary 
atherosclerosis. N Engl J Med. 2011;364:226–235.  
91.  Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L, 
Goldmann B, Katus HA. The prognostic value of serum troponin T in 
unstable angina. N Engl J Med. 1992;327:146–150.  
92.  Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk 
of subsequent cardiac events in unstable coronary artery disease. The FRISC 
study group. Circulation. 1996;93:1651–1657.  
93.  Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with 
unstable coronary artery disease who benefit from long-term antithrombotic 
protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study 
Group. J Am Coll Cardiol. 1997;29:43–48.  
94.  Lüscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of 
cardiac troponin T and I for early risk stratification in unstable coronary 
artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial 
ischemia. Circulation. 1997;96:2578–2585.  
95.  Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, 
Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald 
E. Cardiac-specific troponin I levels to predict the risk of mortality in 
patients with acute coronary syndromes. N Engl J Med. 1996;335:1342–
1349.  
96.  Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM. Use of the Centaur 
TnI-Ultra Assay for Detection of Myocardial Infarction and Adverse Events 
in Patients Presenting With Symptoms Suggestive of Acute Coronary 
Syndrome. Clin Chem. 2008;54:723–728.  
97.  Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, Lemos JA de, 
Braunwald E, Cannon CP. Evaluation of the AccuTnI cardiac troponin I 
assay for risk assessment in acute coronary syndromes. Clin Chem. 
2003;49:1396–1398.  
98.  Anderson FP, Fritz ML, Kontos MC, McPherson RA, Jesse RL. Cost-
effectiveness of cardiac troponin I in a systematic chest pain evaluation 
protocol: use of cardiac troponin I lowers length of stay for low-risk cardiac 
patients. Clin Lab Manage Rev. 12:63–69.  
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
82
 
99.  Heeschen C, Hamm CW, Goldmann BU, Moeller RH, Meinertz T. [Cost-
effectiveness of a rapid test for troponin in emergency admissions]. Dtsch 
Med Wochenschr. 1998;123:1229–1234.  
100.  Ostrovskiĭ O V, Brezgina MF, Zaĭtsev VG. [Determination of troponin in 
the diagnosis of acute myocardial infarction in practice: clinico-economic 
analysis]. Klin Lab Diagn. 2009;7–10.  
101.  Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Comparison of a 6-
hour and 9-hour protocol for evaluation of moderate-to-low risk chest pain 
patients in an emergency department diagnostic unit. Singapore Med J. 
2001;42:52–56.  
102.  Fesmire FM, Hughes AD, Fody EP, Jackson AP, Fesmire CE, Gilbert MA, 
Stout PK, Wojcik JF, Wharton DR, Creel JH. The Erlanger chest pain 
evaluation protocol: a one-year experience with serial 12-lead ECG 
monitoring, two-hour delta serum marker measurements, and selective 
nuclear stress testing to identify and exclude acute coronary syndromes. Ann 
Emerg Med. 2002;40:584–594.  
  
APPENDICES 
Appendix A. Study I............................................................................................................. 1 
Appendix B. Study II ........................................................................................................... 3 
Appendix C. Study III ......................................................................................................... 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
 
 
‎APPENDIX A. STUDY I 
APP 1 
Appendix A. Study I  
 
 
 
 
 
 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
APP 2 
 
 
 
 
 
 
 
 
 
‎APPENDIX B. STUDY II 
APP 3 
Appendix B. Study II  
Long-term prognosis of patients with non-ST-segment 
elevation myocardial infarction according to coronary 
artery pathology on coronary angiography 
Karam Sadoon Alzuhairi
1
, Peter Søgaard
1,2
, Jan Ravkilde
1
, Aziza Azimi
3
, Michael 
Mæng
4
, Lisette Okkels Jensen
5
, Christian Torp-Pedersen
3
. 
Affiliations: 
1) Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. 
2) Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 
3) Department of Health, Science and Technology, Aalborg University, Aalborg, 
Denmark 
4) Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark 
5) Department of Cardiology, Odense University Hospital, Odense, Denmark 
 
 
 
 
 
Corresponding author: 
Dr. Karam Alzuhairi 
Department of Cardiology, Aalborg University Hospital 
Hobrovej 18, DK–9000 Aalborg 
Telephone: +45 97664452  
E-mail: ksmajeed76@gmail.com 
 
ASPECTS OF MYOCARDIAL INFARCTION INCIDENCE AND PROGNOSIS 
APP 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
‎APPENDIX B. STUDY II 
APP 5 
Abstract: 
Aims: To examine the long-term prognosis of patients with non-ST-segment 
elevation myocardial infarction (NSTEMI) according to the degree of coronary 
artery disease (CAD).  
Methods and results: We examined 8.889 consecutive patients admitted for first 
time NSTEMI during 2000-2011, to whom coronary angiography was performed. 
Patients were classified by coronary angiography: 0-vessel disease (0VD), diffuse 
atherosclerosis (DA) (0% < stenosis <50%), 1-vessel disease (1VD), 2VD, and 
3VD with stenosis >50%. Follow-up period: 13 years (median 4.5). 
One-year mortality for NSTEMI patients with 0VD was 3.7%, DA 5.7%, 1VD 
2.5%, 2VD 4.8 %, and 3VD 11.5%. Non-diabetic 0VD patients had higher risk of 
mortality than 1VD patients (HR:1.59; 95% CI:1.21-2.02; P<0.001), while those 
with diabetes mellitus (DM) had not significantly different risk. In addition 0VD 
group had higher risk of heart failure (HF) (HR 1.61; 95% CI: 1.39-1.88; P <0.001), 
and lower risk of recurrent MI (HR:0.55; 95% CI:0.39-0.77; P <0.001) compared 
with 1VD. For patients with DA; mortality and HF risks were higher than 1VD and 
not different than 2VD, while recurrent MI risk was not different than 1VD and 
lower than 2VD. 
Finally, the DA group had higher risk of mortality if they had DM, higher risk of 
recurrent MI, and not different risk of HF and stroke compared with the 0VD group 
patients.  
Conclusion: Patients with NSTEMI and non-obstructive CAD (both normal 
coronaries and atherosclerosis) have a comparable prognosis to patients with one- 
or two-vessel disease. Patients with atherosclerosis have worse prognosis than those 
with angiographically normal coronary arteries. 
Key words: Myocardial infarction, prognosis, non-obstructive coronary artery 
disease 
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